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9ABSTRACT
The purpose of this study was to explore bone mineral content (BMC) and bone 
mineral density (BMD) development and related factors in patients with rheumatoid 
arthritis (RA) between 15 and 20 years from disease onset (I), in premenopausal 
women with RA (II), and in young adults with juvenile idiopathic arthritis (JIA) 
(III), and to ascertain osteoporosis (OP) drug use in patients with early RA (IV). 
BMD of the lumbar spine and the femoral neck were measured by dual-energy 
X-ray absorptiometry in patients with RA in two longitudinal studies and in young 
adults with JIA in a cross-sectional study.
In assessing BMD at 15 years from disease onset in an inception cohort of RF-
positive RA patients, it was found that eighteen out of 59 (31%) patients had OP. 
However, the decreases in central bone mineral in this patient group were of low 
degree	and	after	the	subsequent	five	years	no	essential	change	in	central	BMD	was	
found. None of the explanatory variables: sex, age, ESR, HAQ, Larsen score, and 
cumulative prednisolone dose between 15–20 years from disease onset, proved to 
be	a	significant	predictor	of	BMD	change	at	the	lumbar	spine	and	femoral	neck	
from 15- to 20-year check-ups (I).
In assessment of BMC and BMD development in premenopausal, regularly 
cycling RA patients with and without GCs and in controls, it was found that RA 
patients with GCs had lower BMD values than those without GCs at commencement 
of	follow-up.	Furthermore,	the	mean	BMD	decreased	significantly	in	both	lumbar	
spine (P=0.002) and femoral neck (P<0.001) only in the RA patients with GCs 
during	the	2-year	follow-up.	However,	there	was	no	statistically	significant	difference	
between the three groups in change in BMC or projectional area in the lumbar spine 
or femoral neck. Comparing results on bone mineral density change between the 
three groups it is relevant to report changes both in bone mineral content and in 
projectional area to clarify the basics of the bone mineral density change. BMD is 
expressed	as	BMC	per	projectional	area.	Only	weight	was	found	to	be	a	significant	
predictor of BMD change (II).
 Assessment of BMC and BMD development in young adults with JIA and 
controls assumed to have reached their peak bone mass, showed that three (2.6%) 
out of 116 patients with JIA had OP. The male and female JIA patients had lower 
weight- and height-adjusted BMD values in the femoral neck than the controls. 
Dividing the patients into two groups, those with active and those with inactive 
JIA, both groups had lower BMC values in the femoral neck than the controls 
(P<0.001). Comparing BMC values in the femoral neck in both men and women 
with JIA a difference was found only among men (P= 0.006). Among men, use of 
10
ABSTRACT
GCs	and	weight	were	significantly	associated	with	BMC	in	the	femoral	neck.	Among	
women,	use	of	GCs,	weight	and	also	height	were	associated	statistically	significantly	
with BMC in the femoral neck, and among women GC use and height were also 
associated with BMC in the lumbar spine (III).
A total of 14 878 incident cases of RA were studied when evaluating the 
implementation of pharmaceutical OP drug use. Out of this total, 1351 (9%) patients 
with	RA	had	purchased	OP	drugs,	mainly	bisphosphonates,	during	the	first	year	
after commencement of antirheumatic treatment. Of GC users, 14% of women 
and 6% of men were prescribed OP drugs. In addition, 8% of females and 3% of 
males not taking GCs received OP medication. Women were more prone to use 
OP medication. Of the RA patients who took GCs, 38% of women and 24% of men 
received concomitant calcium and vitamin D preparations by prescription during 
the same year, whereas the corresponding percentages for patients without GCs 
were 21% and 13%. (IV).
Study results suggest that bone loss takes place in earlier disease course in 
RA and JIA and bone loss is in the long-term disease course in RA of low degree. 
Further studies are needed to elucidate bone loss and OP development in early 
rheumatoid arthritis and to better focus the timing and means of OP prevention.
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TIIVISTELMÄ
Lannerangan ja reisiluun kaulan luunmäärän muutokset nivelreumaa pitkään 
sairastaneilla aikuisilla ja premenopausaalisilla naisilla, sekä aktiivista että 
remisiossa olevaa lastenreumaa sairastavilla nuorilla aikuisilla huomioiden 
nivelreumaa sairastavien osteoporoosilääkkeiden käyttö.
Luun määrää ja luuntiheyttä sekä niihin vaikuttavia tekijöitä tutkittiin kahdessa 
nivelreumapotilaiden seurantatutkimuksessa ja lastenreumaa sairastavien nuorten 
aikuisten poikittaistutkimuksessa. Nivelreumapotilaiden osteoporoosilääkkeiden 
käyttöä vuosina 2000–2007 tutkittiin Kansaneläkelaitoksen rekistereistä 
huomioiden kortisonia käyttävien nivelreumapotilaiden luuston suojaaminen.
Ensimmäisessä osatyössä varhaiseen seropositiiviseen nivelreumaan 
sairastuneita aikuisia oli seurattu vuodesta 1973–1975 Reumasäätiön sairaalassa, 
Heinolassa. 74 potilasta osallistui 15-vuotisseurantaan ja uudelleen 59 potilasta 
20-vuotisseurantaan, jolloin heiltä mitattiin lannerangan ja reisiluun kaulan 
luuntiheydet. Tutkittavien taudin aktiivisuutta, toimintakykyä, reumalääkkeiden 
ja kortisonin käyttöä arvioitiin. Osteoporoosia löytyi 15 vuotta nivelreumaan 
sairastumisesta noin kolmannekselta potilaista. Noin puolella nivelreumapotilaista 
olivat lievästi alentuneet luuntiheysarvot. Verrattaessa luuntiheyksiä saman 
ikäiseen väestöön nivelreumapotilaiden luuntiheydet olivat vain lievästi alentuneet. 
Tutkittavien luuntiheyksissä lannerangassa ja reisiluun kaulassa ei tapahtunut 
juurikaan muutosta viiden vuoden seurannan aikana. Mikään tutkituista kliinisistä 
tekijöistä ei selittänyt luuntiheyksien muutosta.
Toisessa osatyössä 74 nivelreumaa sairastavan naisen sekä 43 terveen verrokin 
lannerangan ja reisiluun kaulan luuntiheydet mitattiin tuplamittauksin kahden 
vuoden välein. Tutkittavilla oli säännöllinen kuukautiskierto eivätkä he olleet 
vaihdevuosissaan. Nivelreumaa sairastavat aikuiset jaettiin kahteen ryhmään: 
kortisonia käyttäviin (48) sekä kortisonia käyttämättömiin (26). Tutkittavien 
taudin aktiivisuutta, toimintakykyä, reumalääkkeiden ja kortisonin käyttöä 
arvioitiin. Seurannan alussa kortisonia käyttävillä oli alhaisemmat luuntiheysarvot 
lannerangassa ja reisiluun kaulassa kuin kortisonia käyttämättömillä reumaa 
sairastavilla. Kahden vuoden seurannassa lannerangan ja reisiluun kaulan 
keskimääräisen luuntiheyden lasku oli merkitsevä vain kortisonia käyttävien 
nivelreumaa sairastavien ryhmässä. Kuitenkin, kun tarkasteltiin luun määrän ja sen 
mitta-alueen pinta-alan muutosta seurannan aikana, ryhmien välillä lannerangassa 
ja reisiluun kaulassa ei havaittu merkitsevää muutosta. R.P. Heaney (2005) on 
pääkirjoituksessaan vaatinutkin, että seurantatutkimuksissa tulisi ryhmien välistä 
luuntiheyden muutosta aina tarkastella luunmäärän ja sen mitta-alueen pinta-alan 
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muutoksena. Tutkituista kliinisistä tekijöistä vain paino oli yhteydessä luuntiheyden 
muutokseen.
Kolmannessa osatyössä 116 lastenreumaa sairastavan nuoren aikuisen ja 68 
saman ikäisen verrokin lannerangan ja reisiluun kaulan luuntiheydet mitattiin. 
Lastenreumaa sairastavat aikuiset oli jaettu kahteen ryhmään: aktiivista tautia 
sairastaviin sekä niihin, joilla ei voitu enää havaita taudin aktiivisuutta viimeiseen 
kahteen vuoteen. Lastenreumaa sairastavien aikuisten reisiluun kaulan luuntiheydet 
olivat alentuneet verrattuna verrokkeihin, erityisesti miehillä. Paino ja kortisonin 
käyttö olivat yhteydessä alentuneeseen luuntiheyteen. Osteoporoosia oli vain 
2,6%:lla nuorista aikuisista lastenreumapotilaista.
Neljännessä osatyössä tutkittiin Kansaneläkelaitoksen rekistereistä vuosina 
2000–2007 nivelreumalääkkeiden erityiskorvattavuuden juuri saaneiden 
nivelreumapotilaiden reseptillä ostamien osteoporoosilääkkeiden ja kortisonin 
käyttöä. Rekisteritietoa analysoitiin neljänä kahden vuoden jaksona, alkaen vuodesta 
2000. Naisia 14 878 nivelreumapotilaasta oli 68% ja heistä iältään yli 55vuotiaita 
oli 55%. Ensimmäisen vuoden aikana lääkekorvattavuuden myöntämisestä 
osteoporoosilääkkeitä oli ostanut 9% nivelreumapotilasta, pääosin bisfosfonaatteja. 
Kalsium- ja D-vitamiinivalmisteita oli reseptillä ostanut 26% nivelreumapotilaista. 
Kortisonia käytti noin puolet nivelreumapotilaista vuosina 2000 – 2005. Heistä 24% 
miehistä ja 38% naisista oli ostanut reseptillä kalsium- ja D-vitamiinivalmistetta. 
Vastaavasti kortisonia käyttämättömistä nivelreumapotilaista 13% miehistä ja 21% 
naisista oli ostanut kalsium- ja D-vitamiinivalmisteita. Nivelreumapotilaista, jotka 
käyttivät kortisonia, osteoporoosilääkkeitä oli ostanut 6% miehistä ja 14% naisista, 
kun vastaavat luvut kortisonia käyttämättömillä nivelreumapotilailla olivat miehillä 
3% ja naisilla 8%. Varhaista nivelreumaa sairastavilla osteoporoosilääkkeiden käyttö 
oli vähäistä ja tavallisinta iäkkäillä naisilla.
Havaittiin, että pitkään nivelreumaa sairastaneiden potilaiden lannerangan 
ja reisiluun kaulan luuntiheyden muutokset seurannan aikana olivat vähäisiä. 
Premenopausaalisilla nivelreumapotilailla havaittiin samantyyppinen muutos. 
Seurattaessa luuntiheyden muutosta ryhmien välillä on aina syytä tarkastella 
luuntiheyden muutoksen lisäksi myös luunmäärän ja sen mitta-alueen pinta-alan 
muutosta. Lastenreumaa sairastavilla nuorilla aikuisilla osteoporoosi oli vähäistä. 
Varhaista nivelreumaa sairastavien ja kortisonia käyttävien osteoporoosilääkkeiden 
reseptiostot oli vaatimattomat ensimmäisen vuoden aikana nivelreuman hoidon 
lääkekorvattavuuden myöntämisestä.
Lisätutkimuksia tarvitaan nivelreumaa sairastavien luuntiheyden muutoksen 
ja vaikuttavien tekijöiden selvittämiseksi.
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1 INTRODUCTION
‘Osteoporosis is a disease characterised by low bone mass and micro-architectural 
deterioration of bone tissue, leading to enhanced bone fragility and a consequent 
increase in fracture risk’ according to a study group appointed by the World Health 
Organization (WHO) 1994. The major fall in bone mineral density (BMD) at all 
sites is related to menopause (Kröger et al. 1992a, 1994, Ravn et al. 1994, Sirola 
et al. 2003a). Thus, postmenopausal bone loss is a strong confounding element in 
efforts to explain factors underlying axial bone loss among women.
Glucocorticosteroid-induced osteoporosis (GIO) is a form of secondary 
osteoporosis (OP) and is associated with prolonged use of glucocorticosteroids 
(GCs)	in	various	inflammatory	chronic	illnesses	such	as	rheumatoid	arthritis	(RA)	
and juvenile idiopathic arthritis (JIA) (ACR 2001). Furthermore, the role of GCs 
in	bone	loss	among	patients	with	RA	is	controversial	and	their	benefit-risk	ratio	
varies among individual patients (Strand and Simon 2003).
The most serious outcome of OP in patients with RA is fractures (Hooyman 
et al. 1984). The hip fracture risk is approximately doubled in RA patients and 
among those taking GCs (Cooper et al. 1995). GC use predicts a vertebral fracture 
risk even in patients with early RA (Michel et al. 1991, Peel et al. 1995). Van Staa 
and associates (2000) observed a GC dose dependence of fracture risk in their 
large retrospective cohort study conducted in a general medical practice setting. 
All fracture risks declined rapidly toward baseline after cessation of GC treatment.
Both ACR and EULAR have published recommendations for the prevention of 
OP in patients with rheumatic diseases and those who receive GC treatment. When 
an RA patient is started on prednisolone > 7.5mg daily for over three months, 
calcium and vitamin D supplementation should also be prescribed. Antiresorptive 
therapy should be considered when fracture risk factors are present (ACR 2001, 
Hoes et al. 2007).
Patients with JIA may not achieve optimal peak bone mass (PBM) during 
their growth and sexual maturation (Bianchi et al.1999). Disease activity itself and 
prolonged therapy with GC during childhood may affect patients’ growth through 
various mechanisms (Woo 1994, Wang et al. 2002). Discontinuation of GC therapy 
has led to catch-up growth in 70% of children and the possibility to achieve greater 
final	height	(Simon	et	al.	2002).	Stagi	and	colleagues	(2010)	revealed	that	children	
with JIA had delayed age at puberty onset in both boys and girls compared to the 
healthy Italian population. 
BMD measurement forms the basis for the diagnosis of OP. BMD is measured 
as bone mineral content (BMC) per projectional area by dual X-ray (DXA)-
16
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absorptiometry and expressed as g/cm² (WHO 1994). When measuring BMD in 
a subject over time, it is essential to distinguish between a true change in BMD 
and	a	random	fluctuation	related	to	variability	in	measurement	procedure	such	as	
technician variability, patients’ movements or other unpredictable sources (Nguyen 
et al. 2000, Phillipov et al. 2001, Lodder et al. 2004b). Heaney (2005) has stated in 
his editorial that ʻ all densitometric comparisons between groups should be based on 
BMC	and	area	measurements,	and	that	any	use	of	BMD	must	be	explicitly	justifiedʼ. 
When comparing BMD changes over time, differences may be due to change in 
either BMC or projectional area or both (Hui et al. 2002).
RA is a chronic disorder with joint involvements and a variety of systemic 
manifestations causing functional impairment (Aletaha et al. 2010). Longitudinal 
studies have rarely been conducted on BMC and BMD measurements by DXA in 
patients with RA with disease duration exceeding over 10 years and follow-up times 
reaching two years or more (Hall et al. 1994, Buckley et al. 1997, Miyamoto et al. 
1999, Haugeberg et al. 2002, Shibuya et al. 2002, Krieckaert et al. 2013).
17
2 REVIEWS OF THE CONCEPTS
2.1 EVALUATION OF BONE MINERAL DENSITY
Devices for every-day clinical use to assess noninvasively BMD in the human 
skeleton are decribed below. Portable, low-cost X-ray absoptiometry (pDXA) and 
quantitative ultrasound (QUS) devices for measurements of the peripheral skeleton, 
(heel, forearm and hand) have been developed for ready patient access to bone 
densitometry scanning. They are recommended for screening purposes, but not 
for diagnosis of OP (Kröger et al. 1995, Hans et al. 1996, Glüer 1997, Blake et al. 
2005, Hans et al. 2008). Quantitative computed tomography (QCT) and peripheral 
pQCT allows 2D- and 3D-volumetric analyses of trabecular and cortical bone 
(Adams 2009). Digital X-ray radiogrammetry (DXR) is seeing a new renascence 
with	automatic	X-ray	film	reading	software	(Ward	et	al.	2003).	In	all,	dual	X-ray	
absorptiometry (DXA) has emerged as the “golden standard of BMD measurement” 
device and is the most widely used technique in clinical trials and epidemiologic 
studies (Genant et al. 1994, Blake and Fogelman 2009). 
In both the photon absorptiometric (SPA) and the single X-ray (SXA) 
absorptiometric method, an analyzer measures both the transmitted radiation 
and the radiation attenuation at the measurement site. The analysis relies on the 
determination of differences in absorption values of iodine, hydroxyapatite in bone 
and soft tissues (water, proteins and fat) (Cameron and Sorenson 1963, Jacobson 
1964). The absorptiometry is applied to the peripheral skeleton - like radius in distal 
parts of the forearm and calcaneus in the lower leg. The measurement requires a 
constant soft tissue path length, usually achieved by immersion in a water bath. 
The precision of measurement is 1–2%, the accuracy 4–6% (Cameron et al. 1968, 
Mazess and Cameron 1972, Kelly et al. 1994). 
In dual-photon absorptiometry (DPA) two photoelectric peaks are applied, 
allowing density to be measured independently of soft-tissue thickness and 
composition. DPA is applied to the BMD measurement of the axial skeleton, the 
lumbar spine, proximal femur and total body (Christiansen et al. 1975, Christiansen 
and Rödbro 1977). Precision varies according to the measurement site: 1.4–3.7% 
at the lumbar spine, 3–5% at the hip. Accordingly, the accuracy is 5–10% at the 
lumbar spine and the hip (Christiansen and Rödbro 1977, Mazess and Barden 1988).
QCT utilizes X-rays and gathers information on a slice through the body using a 
rotate-translate scan mode and multiple rings of detectors. The tissues have different 
linear	X-ray	absorption	coefficients	and	all	clinical	body	computer	tomography	(CT)	
scanners are similarly calibrated to the X-ray attenuation of water, which is measured 
18
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in	Hounsfield	units	(HU).	Bone	absorbs	more	X-rays	and	has	a	higher	HU	figure	
than water. HU can be transformed into bone mineral equivalents (g/cm³) using 
the	bone	equivalent	phantom	in	the	scan	field.	2D-	and	3D-volumetric	analyses	
give more information on cortical and trabecular bone qualities. In central QCT 
lumbar vertebrae L1–L3 are measured and expressed as trabecular BMD in mg/
cm³ of individual vertebrae scanned and as a mean BMD (Rüegsegger et al. 1976, 
Elsasser and Reeve 1980). The precision of QCT at the lumbar spine is 1.0–1.5% and 
the accuracy lies variably between 5% and 15% (Adams 2009). Peripheral QCT is 
applied to certain regions of the non-dominant forearm or tibia. Depending on the 
measurement site the parameters measured are expressed as total and trabecular 
BMC and BMD, shaft cortical BMC and BMD with many geometric parameters 
(Genant et al. 1982). Precision is 1–2% and accuracy lies between 2% and 8% at 
the radius (Genant 1997, Adams 2009, Engelke et al. 2009).
In DXR, an X-ray of the non-dominant hand is taken. The method was previously 
applied to the mid-point of the second metacarpal bone, but today it covers the second 
to fourth metacarpals, distal radius and ulna. Measurements of the total width and 
medullar width of a bone can be used to calculate several indices of bone status, 
for example the ratio of total bone width to cortical thickness, percentage cortical 
thickness, cortical area, the so-called Exton-Smith index, which is related to cortical 
area and surface area (Exton-Smith et al. 1969). Today the analysis is automated 
and errors are reduced considerably, to 1%, by using a digitiser inter- and intra-
operator. The average BMD of the radius, ulna and second to fourth metacarpals is 
calculated. The precision of DXR lies between 0.68–0.61% (Jørgensen et al. 2000, 
Ward et al. 2003, Elliot et al. 2005). This method is recommended for screening 
purposes only (Reed et al. 2004).
In QUS, ultrasound is passed through bone. Bone has a mechanically anisotropic 
structure,	which	ultrasound	parameters	are	thought	to	reflect.	The	velocity	(SOS)	
and attenuation of transmitted ultrasonic waves (BUA) can be measured (Antich 
et al. 1991, Poet et al. 1994). Precision varies between 4–6% (Glüer et al. 1992, Poet 
et al. 1994). QUS measurements are applied to peripheral bone, mostly the heel 
(Kröger et al. 1995, Hans et al. 1996, Glüer 1997).
2.1.1 MEASUREMENT OF BONE MINERAL BY DUAL X-RAY ABSORPTIOMETRY
The	X-ray	tube	produces	a	higher	and	more	stable	radiation	flux	in	DXA	than	the	
gadolinium-153 radioisotope source in DPA, which allows increased precision and 
reduced scan times. DXA is applied to measure the BMD in grams /cm² of the 
lumbar spine (L1 to L4), hip (femoral neck, trochanter, Ward´s area), forearm, and 
total body. BMD is expressed as BMC per projectional area, g/cm² (Mazess and 
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Barden 1988). The precision of the posteroanterior DXA examination of the lumbar 
spine and the total hip is 1–2%, the femoral neck and trochanter 2.5%, Ward´s 
area 2.5–5%, peripherally in the distal forearm 1%, and in the calcaneus 1.4%. 
The accuracy of DXA lies between 5% and 10% (Ho et al. 1990, Kanis and Glüer 
2000, Tothill and Hannan 2007, Blake and Fogelman 2008). DXA measurement 
is regarded as a golden standard for BMD measurement and is the most widely 
used technique in clinical trials and epidemiological studies (Genant et al. 1994, 
Blake and Fogelman 2009).
2.1.2 DEFINITION OF OSTEOPOROSIS
Some standard, T-score or Z-score, is required when measured BMD values are 
compared. The T-score is a patient’s result interpreted in terms of the SD from the 
mean of sex-matched peak bone mass (PBM). The Z-score is accordingly interpreted 
in terms of age-matched BMD. In children and young adults up to about 18 years of 
age, interpretation can be made only using the Z-score. The scanner manufacturer 
supplies age-, sex-, and ethnically matched normal reference data (WHO 1994, 
Kanis et al. 2000).
The	WHO	has	defined	OP	as	a	T-score	at	or	below	-2.5	in	the	lumbar	spine,	in	
the femoral neck, and total femur (WHO 1994) Table 1.
Table 1. World Health Organization study group osteoporosis classification according to T-score.
Diagnosis T-score
Normal > –1.0
Osteopenia < –1.0 , > –2.5
Osteoporosis < –2.5
Severe osteoporosis < –2.5 plus fragility fractures
2.2 FACTORS AFFECTING BONE MINERAL DENSITY 
DEVELOPMENT
2.2.1 GENETIC DETERMINANTS
Genes affecting estrogen receptors and vitamin D receptors are involved in 
calcium homeostasis (Morrison et al. 1992, Sano et al. 1995). Genes determining 
neuroendocrine	and	inflammatory	systems	also	appear	to	have	an	effect	on	bone	
(Stewart and Ralston 2000, Kung and Huang 2007). The condition seems to 
be determined by the effects of several genes on bone mass and structure, bone 
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turnover, bone loss and fracture risk (Gennari and Brandi 2001, Baldock and Eisman 
2004, Brown et al. 2005, Ralston and Uitterlinden 2010). Family-based and twin 
studies have revealed that the heritability of gaining bone mass lies between 50–85% 
(Dequeker et al. 1987, Pocock et al. 1987, Zhai et al. 2009). There may be a familial 
predisposition to low BMD (Eisman 1999). In twin studies, heritability explains 
over all 56% of bone loss variance (Eisman 1999). A family history of fracture is a 
significant	risk	factor	for	fracture	(Keen	et	al.	1999).	In	osteogenesis	imperfecta,	
OP is inherited in a simple Mendelian manner (Rowe 1991).
2.2.2 PUBERTY, NUTRITIONAL FACTORS AND PHYSICAL ACTIVITY
The pre-pubertal growth spurt attaining height occurs about two years earlier in 
girls than boys. Girls are closer than boys to their predicted adult height peak at 
the same age and at the same pubertal stage (Clastre et al. 1990, Bonjour et al. 
1991, Kröger et al.1992b).
PBM	is	defined	as	the	amount	of	bone	present	in	the	skeleton	at	the	end	of	the	
maturation process. It is mainly achieved between Tanner stages 2 and 4 of pubertal 
maturation and is completed by the end of the second decade of life (Bonjour et 
al. 1994, Bailey et al. 1999, Harel et al. 2007). Later menarcheal age in women is 
a risk factor for OP, though here genetic determinants of low bone mass and later 
puberty could be involved (Grainge et al. 2001, Chevalley et al. 2009).
Nutritional factors such as a balanced diet with adequate calory and calcium 
intake, are essential for normal growth and suitable PBM (Lloyd et al. 1996, Mølgaard 
et al. 2001, Nordin 2009, Greene and Naughton 2011). There seems to be a threshold 
of calcium intake, about 400mg per day, under which increasing intake of calcium 
is	beneficial	 for	children	(Matkovic	and	Heaney	1992).	The	recommended	daily	
allowance of calcium varies according to age, pregnancy and lactation. The daily 
intake recommended in Finland is shown in Table 2.
Table 2. Recommended daily calcium intake according to the National Nutrition Council of Finland
Group Age,
years
Recommended daily 
calcium intake, mg
Newborns >0.5 
0.5.1
360 
540
Children 1—6 
7—10
600 
700
Youngsters 11—20 900
Adults 21—60 800
Pregnant or Weaning 900
Elderly >60 800
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Vitamin D has an important role in calcium homeostasis, increasing intestinal 
absorption of calcium and inhibiting parathyroid hormone synthesis and secretion 
(Lips	2001).	Severe	vitamin	D	deficiency	leads	to	rickets	in	children	and	osteomalacia	
in adults, which in turn leads to bone deformities and increasing fracture risk 
(Lips et al. 1996, Heaney et al. 2000). Systematic vitamin D supplementation is 
recommended in infancy and in subjects not exposed to adequate solar UV radiation 
or vitamin D intake (Lehtonen-Veromaa et al. 1999, Outila et al. 2001, Viljakainen 
et al. 2006) Table 3.
Table 3. Recommended daily intake of vitamin D3 according to the National Nutrition Council of Finland
Under 2 years of age 10 µg 10 µg vitamin D3 preparation throughout the yearly 
recommended
2–74 years of age 10 µg From 2 to 18 years of age 7.5 µg vitamin D3 preparation 
recommended for the whole year. From 60 years of age 
20 µg vitamin D3 preparation throughout the yearly 
recommended
75 years of age and over 20 µg 20 µg vitamin D3 preparation throughout the yearly 
recommended
Pregnant or weaning women 10 µg 10 µg vitamin D3 preparation throughout the yearly 
recommended
There seems to be a window of opportunity to increase PBM by active physical 
exertion during pubertal development, especially combined with adequate calcium 
intake (Welten et al. 1994, Bonjour et al. 2001, Sundberg et al. 2001). Physical 
activity and particularly load-bearing exercise contributes to maintaining bone mass 
(Slemenda et al. 1991). Muscle mass and strength predict bone strength (Daly et 
al. 2008). 
2.2.3 PREMENOPAUSAL BONE LOSS, PARITY, LACTATION AND MENOPAUSE
Young women may lose bone mass during amenorrhea (Miller and Klibanski 1999, 
Davies et al. 1990, Grainge et al. 2001, Ducher et al. 2009). Human lactation, weaning 
and postpartum amenorrhea, and resumption of menses induce reversible bone 
loss. It is suggested that during pregnancy and lactation, calcium needed for fetal 
and infant skeletal growth is drawn from the maternal skeleton (More et al. 2001). 
A systematic bone loss occurs during lactation and postpartum amenorrhea. BMD 
recovers after resumption of menstruation despite continued lactation (Holmberg-
Marttila et al. 2000). Multiple pregnancies and extended lactation are not to be 
considered risk factors for future OP (Laskey and Prentice 1999, Karlsson et al. 2001).
Reduction in body weight induces bone loss in premenopausal women (Salamone 
et al. 1999, Fogelholm et al. 2001), whereas gain in body weight even protects from 
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premenopausal bone loss (Uusi-Rasi et al. 2002, Bainbridge et al. 2004). Physical 
activity and adequate calcium intake help to maintain bone mass (Fehily et al. 1992, 
Uusi-Rasi et al. 2002, Mein et al. 2004). Sex steroids and possibly early menarche 
are important for the maintenance of bone mass before menopause (Slemenda et 
al. 1996, Hui et al. 2002, Bainbridge et al. 2004).
Bone loss in the axial bone varies from a yearly bone gain of +0.3% in the lumbar 
spine, in the hip to a minor yearly bone loss of -0.3–1.0% in the lumbar spine, and 
-0.25%–0.6% in the hip according to study design, absorptiometry used, population 
measured and follow-up time (Ravn et al. 1994, Slemenda et al. 1996, Sowers et al. 
1998, Salamone et al. 1999, Chapurlat et al. 2000). 
The menopause in women is the result of physiological ovarian failure (Brambilla 
and McKinlay 1989). BMD loss is related to menopause. It would appear that bone 
loss in BMD at all sites is accelerated during the early years of menopause and 
then decreases (Kröger et al. 1994, Ravn et al. 1994, Sirola et al. 2003a). Periosteal 
apposition occurs and causes expansion of the medullar cavity of bone, increasing 
bone size. Periosteal apposition is inversely associated with postmenopausal 
estradiol levels (Ahlborg et al. 2003). Changes in body weight and especially weight 
loss are associated with postmenopausal bone loss. Bone markers, life style, smoking, 
alcohol use, physical activity, and nutritional factors do not seem to be associated 
(Sirola et al. 2003b). In longitudinal studies the mean annual postmenopausal 
bone loss in BMD lies between 0.2 to 2.1% according to the bone site measured 
and the method used (Riggs et al. 1986, Dennison et al. 1999, Melton et al. 2000, 
Uusi-Rasi et al. 2001, Warming et al. 2002, Sirola et al. 2003a). 
2.3 OSTEOPOROSIS
2.3.1 CLASSIFICATION OF OSTEOPOROSIS
Primary OP is unassociated with any other disease function. It is related only to 
age (senile) and decreased hormonal production (postmenopausal). Secondary OP 
is related to certain medical conditions and medications, for example endocrine 
or metabolic causes, collagen and genetic disorders or nutritional factors, and 
medicines such as GCs (WHO 1994).
2.3.2 PROPHYLAXIS AND DIAGNOSIS OF OSTEOPOROSIS
Primary prevention of OP entails preventing the development of OP. The objective 
is peak bone acquisition in youngsters and preservation of bone mass. Educational 
resources are utilized. Nutritional factors such as adequate intake of calcium and 
vitamin D are advocated (WHO 1994).
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Secondary prevention of OP comprises early detection of the disease or its 
precursors. It may thus have two major perspectives (WHO 1994, Kanis et al. 1994). 
Firstly, BMD can be measured in detecting those with low BMD values. Secondly, 
the individual fracture risk can be assessed according to known risk factors such 
as female gender, age, previous fragility fracture, family history of hip fracture, GC 
therapy,	 low	body	weight,	prolonged	immobilization,	vitamin	D	deficiency,	 low	
calcium intake, excessive alcohol consumption, and cigarette smoking (Espallargues 
et	al.	2001,	Kanis	2002).	The	challenge	 is	 to	find	those	 individuals	who	run	an	
increased risk of OP and for fracture.
Unfortunately, fractures occur over a range of bone densities (Siris et al. 2001). 
There	 is	no	exact	cut-off	point	 for	a	 fracture	to	occur.	This	makes	classification	
problematic. The WHO study group in 1994 selected a diagnostic guide for BMD 
measurements. OP is based on comparison of BMD values against a standard of 
healthy young women. It states ´a measured value of bone mineral density more 
than 2.5 standard deviations below the mean for young healthy adult women at 
any	site	(spine,	hip	or	mid	radius)	identifies	30%	of	all	post-menopausal	women	
having osteoporosis, more than half of whom will have sustained a prior fracture 
of the proximal femur, spine, distal forearm, proximal humerus or pelvis´ (Kanis 
et al. 1994, Kanis and Glüer 2000). It would thus appear that BMD values will 
predict future fracture risk and resources of BMD measurements should be aimed 
at those with a high risk of fracture (Kanis 2002).
When the future facture risk of an individual is estimated three groups of 
individuals come into question. Two of these groups comprise such individuals 
who either have so high risk factors for fracture and OP that they do not need a 
BMD measurement to start treatment, or they have so low risk factors for fracture 
or OP that in any ease they do not need any treatment. In between lies a group of 
individuals who do need a BMD measurement to identify the need for OP treatment 
(Kanis 2002). 
2.3.3 TREATMENT OF OSTEOPOROSIS
Calcium and vitamin D supplementation is the basis for OP treatment, aiming also 
at preventing fractures (Bischoff-Ferrari et al. 2005, Bischoff-Ferrari and Dawson-
Hughes 2007).
Major pharmacological interventions comprise selective estrogen-receptor 
modulators (SERMs), bisphosphonates, calcitonin, strontium ranelate, agents 
derived from parathyroid hormone (PTH) and denosumabi (Delmas 2002). 
Hormone replacement therapy among peri- and postmenopausal women holds 
up bone loss and may reduce the fracture risk (Kiel et al. 1987, Torgerson and Bell-
Syer 2001a, 2001b, Delmas 1997).
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SERMs are non-steroidal agents which bind to estrogen receptor and act as 
estrogen agonists or antagonists depending on the target tissue. Raloxifene is a 
benzothiopene and an estrogen agonist on bone (Fontana and Delmas 2001). The 
effect of raloxifene in reducing the risk of vertebral fractures in postmenopausal 
women with OP has been studied in a 3-year Multiple Outcomes of Raloxifene 
Evaluation (MORE) study (Ettinger et al. 1999). The antiestrogen tamoxifen is 
used mainly in women with breast cancer, but it also protects bone (Love et al. 
1992, Grey et al. 1995).
Bisphosphonates are pyrophosphate analogues having two PO3 phosphonate 
groups covalently linked to carbon. They can be divided into nitrogen-containing 
and	non-nitrogen-containing.	Bisphosphonates	have	a	very	high	affinity	for	bone	
and inhibit the resorption of bone by osteoclasts, thus turning homeostasis of 
bone towards bone formation. The potency of bisphophonates in inhibiting bone 
resorption varies, but their half-life in bone is prolonged (Russell et al. 2008). The 
ability of alendronate to reduce the risk of vertebral and non-vertebral fractures 
among postmenopausal women has been studied in the Fracture Intervention Trial 
(FIT) and in its vertebral fracture and clinical fracture arms (Black et al. 1996, 
2000). The Health Outcomes and Reduced Incidence with Zolendronic Acid Once 
Yearly (HORIZON) Pivotal Fracture Trial assessed the effects of annual infusions 
of zolendronic acid on fracture risk during a three-year period (Black 2007). The 
effect of risedronate on vertebral fractures in women during a three-year period 
has	been	studied	in	the	Vertebral	Efficacy	with	RisendronateTherapy	(VERT)	Study	
Group (Reginster et al. 2000). Cranney and associates (2001) reviewed the effect 
of etidronate on fractures in postmenoausal women in a meta-analysis. The Oral 
Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe 
(BONE) evaluated the effect of ibandronate on the fracture risk in postmenoausal 
women after three years of use (Chesnut et al. 2004).
Calcitonin is an endogenous polypeptide hormone produced in the thyroid gland 
and exerts its action on osteoclasts, inhibiting bone resorption (Chesnut et al. 2000). 
A 5-year Prevent Recurrence Of Osteoporotic Fractures (PROOF) study revealed that 
nasal calcitonin may reduce the risk of vertebral fractures, while its effect on non-
vertebral fractures is controversial (Chesnut et al. 2000). The European Medicines 
Agency has recommended (20.07.2012) that the nasal formula of calcitonin should 
not be used for OP treatment due to an increased cancer risk (European Medicines 
Agency 2012).
Strontium ranelate contains strontium between ranelatic acid molecules. It has 
a dual mode of action in increasing bone formation and reducing bone resorption 
(Meunier et al. 2004). It was shown to lower the risk of vertebral fractures among 
postmenopausal women during a three-year period in the Spinal Osteoporosis 
Therapeutic Intervention (SOTI) study (Meunier et al. 2004). The effect of strontium 
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ranelate on non-vertebral factures has been evaluated in the Treatment of Peripheral 
Osteoporosis (TROPOS) study (Reginster et al. 2005). The European Medicines 
Agency has recommended (21.02.2014) due to an increased risk of serious cardiac 
events and venous thrombosis that strontium ranelate be indicated only in those 
postmenopausal women and those men who have a high fracture risk and cannot be 
treated with other medicines approved for OP (European Medicines Agency 2014).
Agents derived from parathyroid hormone comprise the intact molecule with 
1–84 amino acids and the 1–34 N-terminal fragment (teriparatide). They are given 
daily subcutaneously, mimicking intermittent administration of PTH, leading to 
an increase in bone mass and in an improvement in skeletal architecture (Jiang et 
al. 2003, Chen et al. 2007). They have been shown to reduce the risk of vertebral 
fractures (Neer et al. 2001, Greenspan et al. 2007). Teriparatide has proved to have 
a similar effect on non-vertebral fractures (Neer et al. 2001, Krege and Wan 2012). 
Their use has been limited to 24 months, as studies on rats with more long-term 
administration of high doses of teriparatide revealed an increased incidence of 
osteosarcoma (Neer et al. 2001).
Denosumabi is a long-acting human monoclonal antibody affecting osteoclasts 
and inhibiting bone resorption (Miller et al. 2008, 2011). It has been shown to 
reduce the incidence of vertebral and non-vertebral fractures in postmenopausal 
women (Cummings et al. 2009).
Robust long-term studies lasting longer than three years are relatively rare in 
the	context	of	the	OP	treatments.	Studies	for	some	agents	extending	over	five	years	
seem	to	confirm	maintenance	of	BMD	levels	with	indirect	evidence	for	an	additional	
reduction	in	fracture	incidence	(Cooper	et	al.	2012).	The	antifracture	efficacy	up	
to three years of agents used in the treatment of postmenopausal osteoporosis is 
shown in Table 4.
Table 4. Antifracture efficacy up to three years of agents used in treatment of postmenopausal osteoporosis
Agents Vertebral fractures Nonvertebral fractures
Bisphosphonates ᵃ Strong evidence Good evidence
Calcitonin (nasal) ͨ Some evidence No convincing effect
Raloxifene ͩ Strong evidence No convincing effect
Hormone replacement therapy ͤ Good evidence Good evidence
Strontium ranelate ͬ Strong evidence Good evidence
Parathyroid hormone analogues* Strong evidence Good evidence
Denosumabi ͪ Some evidence Some evidence
*Antifracture efficacy shown up to 18 months, Neer et al. 2001, Krege and Wan 2012
ᵃBlack et al. 1996, 2000, 2007, Reginster et al. 2000, Cranney et al. 2001, Chesnut et al. 2004
ͨ Chesnut et al. 2000
ͩ Ettinger et al. 1999
ͤ Torgerson and Bell-Syer 2001a, 2001b
ͬ Meunier et al. 2004, Reginster et al. 2005
ͪ Cummings et al. 2009
26
REVIEWS OF THE CONCEPTS
2.4 RHEUMATOID ARTHRITIS
RA is a chronic disorder of unknown cause with a variety of systemic autoimmune 
and extra-articular manifestations. Its course can vary from mild to severe 
polyarticular	illness	with	erosive	synovial	inflammation	involving	peripheral	joints,	
this being characteristic of RA and manifested in particular as stiffness, pain, swelling 
of the joints of the hands, wrists and foreseeds (Aletaha et al. 2010).
The estimated prevalence of RA is 0.8% in seropositive RA among the Finnish 
population (Aho et al. 1989 and 1998). RA is more prevalent in women than in 
men, with a ratio 2:1. The annual incidence of RA in Finland has varied between 
44.5–32 per 100 000 adults according to studies conducted in 1980, 1985, 1990 
and 1995 (Kaipiainen-Seppänen et al. 1996, Kaipiainen-Seppänen and Aho 2000, 
Kaipiainen-Seppänen and Kautiainen 2006, Puolakka et al. 2010). 
2.4.1 CLASSIFICATION OF RHEUMATOID ARTHRITIS
RA	is	classified	according	to	the	2010	American	College	of	Rheumatology/European	
League Against Rheumatism (ACR/EULAR) criteria based on joint involvement, 
serology,	acute	phase	reactants	and	duration	of	symptoms.	The	goal	in	this	field	is	
to	identify	patients	with	a	relatively	short	duration	of	symptoms	who	may	benefit	
from early institution of disease-modifying anti-rheumatic drug (DMARD) therapy 
or entry into clinical trials of promising new agents which may halt the development 
of the disease (Aletaha et al. 2010).
The chosen criteria are factors which best discriminate in the target population 
between those who are and those who are not at high risk of an erosive disease. 
The	target	population	comprises	patients	having	at	least	one	joint	with	definitive	
clinical synovitis (swelling) and with the synovitis not better explained by another 
disease, i.e. early RA (Kaarela et al. 2012).
‘Definite	RA’	is	based	on	the	confirmed	presence	of	synovitis	in	at	least	one	joint,	
absence of an alternative diagnosis better explaining the synovitis, and achievement 
of a total score of 6 or greater (out of a possible of 10) from the individual scores 
in four domains: number and site of involved joints (range 0–5), serological 
abnormality (range 0–3), elevated acute-phase response (range 0–1) and symptom 
duration (two levels; range 0–1) (Aletaha et al. 2010) Table 5.
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Table 5. The American College of Rheumatology/European League Against Rheumatism  
2010 classification criteria for rheumatoid arthritis
Domains (A-D) Score
Joint involvement
1 large jointª
2–10 large joints
1–3 small joints (with or without involvement of large joints)ͩ
4–10 small joints joints (with or without involvement of large joints
>10 joints (at least one small joint)
0
1
2
3
5
Serology ( at least one test result is needed)
Negative RF and negative ACPA 
Low-positive RF or low-positive ACPA 
High-positive RF or high-positive ACPA
0
2
3
Acute-phase reactants ( at least one is needed)
Normal CRP and normal ESR 
Abnormal CRP or normal ESR 
0
1
Duration of symptoms
<6 weeks
≥6 weeks
0
1
ᵃLarge joints refers to shoulders, elbows, hips, knees and ankles
ͩ Small joints refers to the metcarpophalangeal joints, proximal interphalangeal joints, second to 
fifth metatrsophalangeal joints, thumb interphalangeal joints and wrists.
ACPA anti-citrullinated protein antibody
CRP C-reactive protein
ESR erythrocyte sedimentation rate
2.4.2 CLINICAL CHARACTERISTICS AND TREATMENT OF  
RHEUMATOID ARTHRITIS
Polyarticular joint involvement with tenderness and swelling of the small joints 
of the hands and foreseeds may be a common classic presentation (Ollier et al. 
2001, Aletaha et al. 2010). Patients may report general symptoms such as morning 
stiffness, fever, fatigue, sweats and weight loss. Early peripheral joint destruction 
indicates a more severe disease and would appear to be associated with large joint 
involvement and increased functional disability (Scott et al. 2000, Jäntti et al. 2002). 
Disease activity seems to be associated more with functional capacity in early RA, 
while joint damage is associated with functional capacity in later stages (Welsing 
et al. 2001, Sokka et al. 2003).
Today both ACR and EULAR treatment recommendations include retarding 
disease activity as soon as possible and preventing and halting progression of joint 
damage.	Remission	of	disease,	which	means	absence	of	inflammation	as	determined	
by patient laboratory acute phase reactant and joint assessment, is the goal of 
treatment	 in	RA.	However,	 it	 is	difficult	 to	define	remission	 in	clinical	practice	
(Jäntti et al. 2001, Pincus et al. 2004, 2006, Mäkinen et al. 2005).
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Methotrexate (MTX) is nowadays the anchor drug in treating RA. Combination 
of DMARDs in early RA provides a better clinical response than is the case in 
treatment with a single DMARD (Möttönen et al. 2002, Moreland et al. 2012, de 
Jong et al. 2013). GCs have been used as a long-term low-dose strategy or as a 
bridge therapy when awaiting the effect of a newly started DMARD (van Riel et 
al. 1999, Knevel et al. 2010). Biological agents, which target cytokines and cells of 
the immune system, should be introduced if no response is seen with traditional 
DMARDs (Nam et al. 2010). 
2.5 JUVENILE IDIOPATHIC ARTHRITIS
JIA is a heterogeneous condition emerging in childhood with variable clinical 
manifestations such as morning stiffness, pain, fatigue, and loss of function. Weight 
loss and failure to grow occur in children with severe disease and may lead to 
delayed puberty (Petty et al. 1998).
The	diversity	of	classification	criteria	and	selection	bias	are	major	problems	in	
interpreting and comparing epidemiologic studies on chronic arthritis in children. 
According to the ILAR criteria the incidence rate was 15 per 100 000 children per 
year in the whole group of 315 children with JIA in Scandinavia and 21 per 100 
000 per year in the Helsinki area in Finland (Berntson et al. 2003).
Similar	figures	for	the	incidence	of	JIA	have	been	obtained	in	different	regions	
of Europe (Moe and Rygg 1998, Hanova et al. 2006, Pruunsild et al. 2007, Modesto 
et al. 2010, Solau-Gervais et al. 2010).
2.5.1 NOMENCLATURE AND CLASSIFICATION OF  
JUVENILE IDIOPATHIC ARTHRITIS
The criteria for juvenile rheumatoid arthritis (JRA) were published by the American 
Rheumatism Association (ARA) in 1973 and were further revised by Brewer and 
colleagues in 1977. The age of patients at disease onset lay from 0 to 15 years and 
the disease duration was at least 6 weeks. The subgroups were systemic arthritis, 
pauciarticular	with	one	to	four	joints	affected	and	polyarticular	arthritis	with	five	
or more joints affected.
EULAR published criteria for juvenile chronic arthtritis (JCA) in 1978. Subgroups 
such as systemic arthritis, pauciarticular and polyarticular onset arthritis remained, 
but newer subgroups were introduced: juvenile ankylosing spondylitis (JAS), 
psoriatic	arthropathy	(JPA)	and	arthropaties	associated	with	inflammatory	bowel	
disease. The age of patients at disease onset lay from 0 to 15 years, but the disease 
duration was prolonged to 12 weeks (Wood 1978).
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The Paediatric Standing Committee of the International League of Associations 
for Rheumatology (ILAR) introduced new criteria and the term juvenile idiopathic 
arthritis in 1995 (Fink 1995). These criteria were revised by Petty and associates 
in 1998. JIA can be divided into seven subgroups according to the clinical picture 
during	the	first	six	months:	systemic	arthritis,	oligoarthritis	(1–4	joints),	rheumatoid	
factor (RF)-negative polyarthritis, RF-positive polyarthritis, psoriatic arthritis, 
enthesitis-related arthritis, and other arthritis. The oligoarthritis form may progress 
to a polyarticular disease called extended oligoarthritis after 6 months. The age of 
patients at disease onset lies from 0 to 15 years. The disease duration is 6 weeks at 
minimum (Petty et al. 1998). 
2.5.2 CLINICAL CHARACTERISTICS AND TREATMENT OF  
JUVENILE IDIOPATHIC ARTHRITIS
Articular manifestations and joint destruction can lead to limitations of movement, 
bony overgrowth and chronic disability (Guillaume et al. 2000, Minden et al 2002, 
Flatø et al. 2003, Foster et al. 2003, Packham and Hall 2002, Selvaag et al. 2005). 
The long-term outcome of JIA varies according to the disease sub-type (Zak and 
Pedersen 2000, Oen et al. 2003, Packham and Hall 2002, Ravelli 2004, Adib et 
al. 2005). Persistent oligoarthritis is considered the mildest form and systemic 
arthritis the most severe, with further susceptibility to amyloidosis (Packham and 
Hall 2002, Immonen et al. 2008). 
Uveitis occurs in 5–20% of oligoarthritis patients (Kotaniemi et al. 2001, 2005). 
Other extra-articular manifestations comprise serositis or carditis and are linked 
to systemic onset JIA (Athreya et al. 1980, Svantesson et al. 1983, Goldenberg et 
al. 1992).
Treatment	aims	to	control	the	inflammatory	process,	to	preserve	function	and	
to prevent deformities of the joints. It should be started early and vigorously, the 
objective being to bring about remission (Beukelman et al. 2011). The treatment 
plan needs to be individualized according to JIA subtype (Tynjälä et al. 2011). 
In general, patients are considered to be in remission if they have had no active 
arthritis or extra-articular manifestations and no disease activity as assessed by a 
doctor for the past six months. Unfortunately, there is no agreement on common 
remission criteria (Adib et al. 2005).
It is estimated that 40 to 60% of JIA patients still continue to suffer from active 
disease during adulthood (Zak and Pedersen 2000, Minden et al. 2002, Flatø et al. 
2003, Foster et al. 2003, Arkela-Kautiainen et al. 2005). Treatment is initiated by 
GCs in systemic onset JIA. A milder form such as oligoarthritis without uveitis is 
treated with NSAIDs. Early GCs, preferably intra-articularly, may be introduced until 
the	diagnosis	is	confirmed.	The	second-line	agents	are	DMARDs.	MTX	is	generally	
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considered	the	first	choice	(Beukelman	et	al.	2011,	Huppertz	2011).	Biologic	agents	
such	as	anti-TNF	agents	(etanercept,	 infliximab	and	adalimumab)	are	currently	
available and reserved for refractory JIA (Haapasaari et al. 2002, Pohjankoski et 
al. 2011, Tynjälä et al. 2011).
Multidisciplinary teamwork involving paediatric rheumatologists, rheumatology 
nurses, physio- and occupational therapeutists, social workers, psychologists, 
orthopedists, ophtalmologists and vocational counsellors provides coordinated 
care and rehabilitation besides the drug therapy line (Kuchta and Davidson 2011).
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3 REVIEW OF THE LITERATURE
3.1 BONE MINERAL DENSITY IN RHEUMATOID ARTHRITIS
Disease duration and disease activity are factors threatening to lower bone mass, 
and it has been speculated that bone loss in patients with RA occurs early in the 
disease course (Laan et al. 1993a, Keller et al. 2001, Forslind et al. 2003, Lodder 
et al. 2004a, Tourinho et al. 2005).
In cross-sectional studies the focus has been on differences in bone mass between 
RA patients constantly using, ever-using and never-using GCs. Overall, patients with 
RA, both men and women, have seemed to have lower BMD values in the lumbar 
spine and in the hip than controls (Garton and Reid 1993, Peel et al. 1995, Mateo 
et al. 1995, Cortet et al. 1997, Sinigaglia et al. 2000, Stafford et al. 2000, Haugeberg 
et al. 2000a, 2000b, Nolla et al. 2006).
Laan and associates (1993b) in a double-blind placebo-controlled longitudinal 
study followed patients (N=40) with RA randomized to receive GC treatment or 
placebo for 44 weeks. The total GC dose was 1050 mg prednisone and on average 
7.5 mg per day, which was tapered and stopped between 12–20 weeks. All patients 
were treated with aurothioglucose 50 mg weekly. Patients treated with GC lost mean 
lumbar trabecular BMD by 8.2% and controls gained 1.3% by 20 weeks of follow-
up. They gained in mean lumbar BMD by 5.3% after cessation of GC treatment, but 
the placebo group lost mean lumbar BMD by 1.5% between weeks 20–44. BMD 
was measured by dual-energy quantitative computed tomography. For duplicate 
measurements,	the	in-vivo	coefficient	of	variation	was	6.1%	for	trabecular	and	5.2%	
for cortical bone.
Hall and associates (1994) randomized postmenopausal women with RA to 
receive transdermal estradiol daily or calcium supplementation 400 mg daily for 2 
years. Twenty-one per cent of the patients were taking corticosteroids. A total of 147 
patients (84 in the calcium treatment group and 63 in the hormone replacement 
therapy (HRT) group) completed the study. The mean lumbar BMD increased 
after 2 years by 2.2% and the mean proximal femur BMD decreaseded by 0.41% 
in the HRT group. Correspondingly, the mean lumbar BMD decreased by 1.19% 
and the mean proximal femur by 0.56% in the calcium group. Differences between 
treatment	groups	were	significant	for	the	spine.	BMD	was	measured	by	DXA	Hologic	
QDR	 1000/W	absorptiometry.	The	 coefficient	 of	 variation	 in	 replicate	 in	 vivo	
measurements was 0.9% for the lumbar spine and 1.5% for the proximal femur.
In a three-year prospective randomized, placebo controlled study of the effects 
of calcium 1000 mg and vitamin D 500 IU daily supplementation on bone density 
32
REVIEW OF THE LITERATURE
Buckley and colleagues (1997) followed up 95 out of 133 patients with RA either 
using MTX (N=68) or non using MTX (N=27). Sixty-four out of 74 women 
were postmenopausal and 16% were on HRT. There were 71 users of GC. Their 
prednisolone daily dose was between 3.7–6.2 mg during the follow-up. The change 
in BMD was similar in MTX and non-MTX treated patients. BMD decreased by 
2% in the lumbar spine and increased by 0.85% in the femoral neck. However, 
among those patients (N=28) receiving daily prednisone 5 mg or more, MTX users 
lost	significantly	more	BMD	in	the	lumbar	spine	(-8.08%)	over	3	years	than	non-
MTX	users.	BMD	were	measured	by	Lunar	DPX	absorptiometry.	The	coefficient	of	
variation in BMD measurements was 1.2% for the antero-posterior lumbar spine and 
2.2% for the femoral neck. Lateral measurement of the lumbar spine in 48 patients 
with RA was transformed to antero-posterior by adding the differences between 
the year 1 antero-posterior and lateral BMD value to the baseline lateral value.
A group under Everdingen (2003) randomly allocated patients with early active 
RA (N=81) to receive prednisone 10 mg or placebo and followed them for 2 years. 
No	significant	changes	from	baseline	in	BMD	of	the	lumbar	spine	or	the	hips	were	
seen in either group during the study.
Tengstrand and associates (2007) randomized 58 patients with RA treated with 
5–7.5 mg prednisolone daily for at least 2 years either to withdraw or continue GC 
treatment. Eleven patients out of 26 randomized to stop GC treatment succeeded 
within	1	year.	Their	mean	Z-score	increased	significantly	by	0.50	in	the	 lumbar	
spine and by 0.40 in the femoral neck from baseline to two years. Those not 
succeeding to taper GC treatment gained 0.08 in the lumbar spine and lost 0.08 
in the femoral neck. Among the patients randomized to continue GC treatment there 
was	a	statistically	significant	increase	by	0.35	in	Z-score	in	the	lumbar	spine,	as	
against	a	non-significant	increase	by	0.02	in	the	femoral	neck.	BMD	measurements	
were made by Lunar DEXA and the reference population was the manufacturer’s 
combined European/USA population.
Haugeberg and colleagues (2009) in a randomized double-blind, placebo-
controlled study followed up patients with active early RA (N=20) for 12 months. 
Patients	 received	 infliximab	 +	 methotrexate	 or	 placebo	 +	 methotrexate.	 GC	
treatment was allowed after 14 weeks at the start of the study. The mean BMD 
loss was 1.26% in the lumbar spine and 1.83% in the femoral neck from baseline 
to	54	weeks.	It	was	significant	in	the	femoral	neck	and	in	the	infliximab-treated	
group.	BMD	measurements	were	made	by	Lunar	Expert.	The	percentage	coefficient	
variation in vivo was 2.33% for the lumbar spine and 2.75% for the femoral neck.
There are only few longitudinal studies on patients with RA having both disease 
duration over 10 years, follow-up for at least two years and using DXA measurement 
for axial BMD (Hall et al. 1994, Buckley et al. 1997, Miyamoto et al. 1999, Haugeberg 
et al. 2002, Krieckaert et al. 2013) Table 6. (Appendix).
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3.1.1 BONE MINERAL DENSITY, DISEASE ACTIVITY AND INFLAMMATION IN 
RHEUMATOID ARTHRITIS
In	seeking	to	elucidate	the	role	of	disease	activity	and	inflammation	in	bone	loss	
in patients with RA, joint erosions, ESR, CRP, DAS28 and bone turnover markers 
have been evaluated in longitudinal studies. The lumbar spine, hip, femoral neck 
and hands seemed to be more sensitive to bone loss due to high disease activity, 
inflammation	and	erosions	in	patients	with	early	RA	(Dolan	et	al.	2002,	Forslind	et	
al. 2003, Book et al. 2008, Haugeberg et al. 2009). Bone loss in longer-term RA in 
the lumbar spine, hip, femoral neck and hands seemed to be associated with disease 
duration, and erosions in the hands, DAS28 (Miyamoto et al. 1999, Tengstrand et 
al. 2007, Güler-Yüksel et al. 2009, Wijbrandts et al. 2009, Krieckaert et al. 2013). 
On the other hand, active and early combination treatment with GCs seemed to 
arrest bone loss (Vis et al. 2006, Haugeberg et al. 2009, Wijbrandts et al. 2009).
3.1.2 BONE MINERAL DENSITY AND GLUCOCORTICOIDS IN  
RHEUMATOID ARTHRITIS
There was a high prevalence of vertebral deformities and clinical manifestations of 
vertebral fractures in RA patients on GCs when compared to those without GCs in 
the multicentre, cross-sectional and population-based studies conducted by groups 
under Hooyman (1984) and de Nijs (2001).
Reduced BMD values seem to be met in patients with long-term RA receiving GCs 
compared	to	RA	patients	not	receiving	GCs	or	controls.	It	is	difficult	to	distinguish	
the effects of disease duration and severity of RA from the effect of GC treatment 
on BMD (Cortet et al. 1997, Buckley et al. 1997, Haugeberg et al. 2002, Engvall 
et al. 2011). Gough and associates (1994a) found that those who lost bone most 
continued to evince active disease and were on GC. It is challenging to achieve a 
favorable	benefit	to	risk	ratio	in	GC	use	and	dosage	in	RA	patients,	as	discussed	
by Strand and Simon 2003.
3.1.3 BONE MINERAL DENSITY, DISABILITY AND IMPAIRED PHYSICAL ACTIVITY 
IN RHEUMATOID ARTHRITIS
The Health Assessment Questionnaire (HAQ)-index has been found to correlate 
inversely with BMD development in the lumbar spine and the femoral neck in 
patients with RA (Tengstrand et al. 2007, Book et al. 2008, Haugeberg et al. 2009). 
Sinigaglia	and	colleagues	(2000)	considered	HAQ	score	to	be	significantly	associated	
with the risk of OP.
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3.1.4 EXERCISE AND BONE LOSS IN RHEUMATOID ARTHRITIS
Regular dynamic strength training combined with endurance-type physical activities 
improved muscle strength and physical function, but not BMD, in patients with 
early RA in a randomized two-year study (Häkkinen et al. 2001). A long-term high-
intensity weight-bearing exercise program for RA patients was effective in slowing 
down bone loss in the hip (de Jong et al. 2004). Physical activity reduced bone loss 
in premenopausal women in a two-year study (Tourinho et al. 2008).
3.1.5 OTHER RISK FACTORS FOR BONE MINERAL DENSITY IN  
RHEUMATOID ARTHRITIS
There is scant knowledge as to how life-style factors affect BMD in patients with RA. 
Tengstrand and Hafström 2002 showed that tobacco use had no effect on BMD.
3.2 BONE MINERAL DENSITY IN JUVENILE IDIOPATHIC 
ARTHRITIS
A	group	under	Polito	(1995)	found	a	significant	relationship	between	height	standard	
deviation (HSDS) score, which describes growth and pubertal Tanner stage, and 
BMC in the distal radius in a cross-sectional study of children with JRA. There was 
no	significant	relationship	between	calcium	and	phosphorous	intake	and	BMC.	
Pepmueller and associates (1996) revealed depressed levels of bone formation 
markers	and	a	significantly	lowered	BMD	in	the	lumbar	spine	and	total	body	than	
was the state in healthy controls.
Kotaniemi and colleagues (1997, 1999) found 13 explanatory variables for BMD, 
volumetric BMD (BMDvol) and bone width in cross-sectional studies of children with 
JCA.	Significant	positive	variables	were	body	size	(comprising	age,	height,	weight,	
Tanner	stage),	physical	activity	and	calcium	intake.	Significant	negative	variables	
were	disease	activity	and	GCs.	BMD	and	BMDvol	were	significantly	decreased	in	
the polyarticular subgroup at both the lumbar spine and the femoral neck, whereas 
in	the	oligoarthritis	subgroup	only	BMDvol	was	a	significant	variable	at	the	femur.	
Both Pereira (1998) and Cetin and their associates (1998) revealed in cross-sectional 
studies that there was bone loss in both the lumbar spine and the femoral neck in 
all three subtypes of JCA compared to healthy controls. GCs, disease activity and 
disease duration were important factors in the development of OP.
In a cross-sectional study of 62 children with JIA Valta and group (2007) found a 
low prevalence of OP, and that six out of 62 children had an asymptomatic vertebral 
fracture. No correlation was found between areal BMD or disease characteristics or 
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cumulative GC dose. Burnham and colleagues (2008) revealed that children with 
JIA are at risk of deleterious alternations in cortical bone strength and trabecular 
bone density and are prone to fracture. Markula-Patjas and associates (2012) found 
in a cross-sectional study of 50 patients with polyarticular or a systemic subtype 
of JIA 22% to have vertebral fractures, mostly thoracic. Furthermore, 30% of 50 
patients had sustained at least one peripheral low-energy fracture. Compression 
fractures were associated with high disease activity, high body mass index and high 
recent cumulative doses of GC.
Hopp and associates (1991) in a longitudinal study of children with JRA found 
that	the	lumbar	spine	BMD	in	postpubertal	girls	was	significantly	lower	than	that	
in healthy controls. However, Bianchi and colleagues (1999) stated that the pubertal 
growth spurt and abatement of disease activity helps to maintain bone mass. In a 
randomized controlled trial Lovell and group (2006) found calcium and vitamin 
D supplementation to promote increase in BMD in the total body, but not in the 
lumbar spine in children with JRA.
In a longitudinal study of children with JCA Elsasser and colleauges (1982) found 
risk factors for vertebral fractures to be a longer duration of bed rest, GCs, reduced 
BMD values, and lowered serum levels of vitamin D. Furthermore, a group under 
Varonos (1987) in a retrospective study revealed that a cumulative GC dose of 5 g 
seems to be a threshold for vertebral fracture.
Lien and associates (2005) in a two-year follow-up study of children with JIA 
found	that	at	baseline	there	was	no	significant	difference	in	bone	measurements	
between patients and healthy controls. There was a trend toward higher gains in 
femoral neck BMC and total femoral BMC in the controls. Changes in BMC in the 
lumbar spine and the distal radius were comparable in patients and controls during 
the	follow-up.	The	cumulative	GC	dose	and	previous	GC	use	were	not	significant	
predictors of reductions in bone mass gains.
Stagi and associates (2010)in a partly longitudinal study followed up 89 out 
of 219 children with JIA over their pubertal development, and compared bone 
mass and pubertal development to 80 age- and sex-matched controls. The patients 
showed a reduced bone mass in the lumbar spine at baseline. There was no 
significant	 improvement	 in	bone	mass	 in	any	subsets	with	JIA	except	systemic	
onset in comparison to controls during the follow-up. The onset age for puberty 
was	significantly	delayed	in	both	boys	and	girls	compared	to	the	healthy	Italian	
population.	GC	exposure	 in	 longitudinal	evaluation	correlated	significantly	with	
BMDvol in the lumbar spine in patients with systemic JIA onset compared to other 
JIA subsets.
A group under Havelka (1993) measured BMD in 26 adult women with JCA 
with a disease duration of between 8 to 33 years. BMD in the lumbar spine was 
significantly	lowered	in	6	out	of	26	patients,	all	of	whom	were	in	the	GC-treated	
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subgroup, compared to the healthy controls Table 7. Zak and group (1999) measured 
BMD in the lumbar spine and the femoral neck in 65 adult patients with JCA and 
revealed	that	BMD	in	the	lumbar	spine	and	in	the	hip	were	significantly	lower	than	
in the matched control group. Observed percentages of osteopenia and osteoporosis 
in both the hip and the lumbar spine were higher than expected in patients with 
JCA.	Patients	with	polyarticular	subtype	JCA	had	significantly	lower	BMD	in	the	
hip compared to patients with pauciarticular subtype.
Haugen and associates (2000) measured BMD in the whole body, the femoral 
neck, lumbar spine and distal radius in 145 young adult patients with either persistent 
juvenile	arthritis	(JA)	or	a	history	of	JA.	Patients	with	persistent	JA	had	significantly	
lower BMD at all measured sites compared with healthy subjects. Men with a history 
of JA had BMD values comparable with healthy subjects, but women with a history 
of	JA	had	significantly	lower	BMD	values	in	the	total	body	and	the	femoral	neck.	
Patients with a history of JA reached normal peak bone mass at the lumbar spine 
and forearm, despite the fact that most had had active disease during puberty.
French and group (2002) conducted a population-based study of BMD in 32 
adults with JRA living in Rochester, Minnesota. Fourteen out of 32 subjects had 
osteopenia in at least one measured site, mainly either in the lumbar spine or the 
femoral neck.
Aggarwal and colleaugues (2006) assessed BMD in the lumbar spine, the left 
hip and the distal forearm in 30 men with active JIA and in 23 healthy men. BMD 
was	significantly	lower	in	the	JIA	group	compared	to	controls	at	all	measured	sites.	
Osteopenia was detected in 73.3% of the patients and 26.7% had OP at the lumbar 
spine. Correspondingly, 73% out of 30 patients were osteopenic and 23.3% were 
osteoporotic at the hip. Osteopenia was seen 90% out of 30 patients and 12% had 
OP at the distal radius. The WHO criteria in Caucasian normative data were applied. 
A group under Thornton (2011) measured BMD in the lumbar spine and hip of 71 
women and 16 men with JIA in their young adulthood attending a rheumatology 
clinic. Lowered BMD values were found in lumbar spine and hip in both men and 
women. Those with extended oligoarticular and polyarticular RF-negative subtype 
of JIA had lower BMD values in the hip.
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Table 7. Percentages of osteoporosis in studies of young adults with juvenile chronic arthritis, 
juvenile rheumatic arthritis, juvenile arthritis, and juvenile idiopathic arthritis
Variable Havelka
1993
Zak
1999
Haugen
2000
French
2002
Aggarwal
2006
Thornton
2011
Study
type
Cross-
sectional
Cross-
sectional
Cross-
sectional
Cross-
sectional
Cross-
sectional
Cross-
sectional
N
(Female/Male)
26
(26/0
65
(52/13)
229
(145/84)
32
(27/5)
30
(0/30)
87
(71/16)
Mean age
(SD), years
24 32
(5.7)
Women
24.9
(2.9)
Men
25.2
(3.1)
27.1
(9.1)
22.09
(5.12)
Women
28.7
Men
31.4
Disease
type
JCA JCA JA JRA JIA JIA
Mean
disease
duration (SD),
years
18 26.4
(5.6)
Women
15.6
(2.4)
Men
14.9
(2.1)
NA 11.27
(5.39)
Women
20.6
Men
24.0
Number of
glucocorticosteroid
users
11 28 Women
34
Men
26
4 17
Percentage of 
patients
in remission
NA 20# Women
60
Men
61
NA NA
Densitometry DPA DXA DXA DXA DXA* DXA
BMD measurement
site
Lumbar
spine
Hip
Lumbar
spine
Hip
Lumbar
spine
Hip
Radius
Lumbar
spine
Hip
Lumbar
spine
Hip
Radius
Lumbar
spine
Hip
Percentage of
osteoporosis
NA Lumbar
spine 7.7
Hip 7
9 0 Lumbar
spine   8
Hip    7
Radius 12
Remarks T-score
<-2.0
6/26
Control 
group
N= 65
Control 
group
N=96
Population-
based
cohort
Control
group
N=23
*Caucasian normative data
#Criteria for remission different from those in Haugen et al. 2000
NA= not available
N= number, SD= standard deviation, JA= juvenile arthritis, JCA= juvenile chronic arthritis, 
JIA=juvenile idiopathic arthritis, DPA= dual-photon absorptiometry, DXA= dual X-ray 
absorptiometry 
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3.2.1 BONE MINERAL DENSITY, DISEASE ACTIVITY AND INFLAMMATION IN 
JUVENILE IDIOPATHIC ARTHRITIS
Disease activity, which is measured by ESR and bone turnover markers, appears to 
correlate negatively with bone mineral development in the lumbar spine and hip 
(Zak et al. 1999, Haugen et al. 2000, Aggarwall et al. 2006).
3.2.2 BONE MINERAL DENSITY AND GLUCOCORTICOIDS IN JUVENILE 
IDIOPATHIC ARTHRITIS
Groups under Bardare (1991) and Reed (1991) in longitudinal studies measured 
BMD in the midshaft of radius and ulna by SPA in patients with JRA, and found 
use of GC to have a negative association with BMD. Kotaniemi and associates (1993) 
in a cross-sectional study measured BMD in the lumbar spine and in the femoral 
neck by DXA in patients with JCA, and found GC use to have no correlation with 
BMD. In contrast, groups under Cetin (1998) and Pereira (1998) in cross-sectional 
studies of patients with JCA found especially the negative correlation of GC use 
to prevail in BMD of the lumbar spine. Haugen and colleagues (2000) in a cross-
sectional study of BMD in the lumbar spine and femoral neck in young adults with 
JA found GC use partly to explain variations in BMD.
3.2.3 BONE MINERAL DENSITY, DISABILITY AND IMPAIRED PHYSICAL ACTIVITY 
IN JUVENILE IDIOPATHIC ARTHRITIS
When HAQ, Steinbrocker’s functional classes and various inquiries into physical 
activity have been used to evaluate disability and physical activity, it seems obvious 
that patients who are more disabled and have lower levels of physical activity, will 
have a negative correlation with bone mass development (Zak et al. 1999, French 
et al. 2002, Aggarwall et al.2006, Thornton et al. 2011). Kotaniemi and associates 
(1999) found that calcium intake and physical activity helped to maintain BMD in 
patients with JCA. 
3.2.4 BONE MINERAL DENSITY AND DELAYED PUBERTAL DEVELOPMENT IN 
JUVENILE ARTHRITIS
Disturbed growth patterns and delayed onset of pubertal development may affect 
bone mass development in children with JRA, JCA and JIA. Laaksonen (1966) 
found disturbances in growth in Finnish children with JRA. Further, Berstein and 
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group (1977) and later Liem and Rosenberg (2003) revealed diminished growth 
patterns especially in children with the systemic subset of JRA compared to poly- 
and pauciarticular subsets. Wang and colleagues (2002) estimated that prolonged 
GC treatment for more than one year can lead to irreversible growth impairment 
in children with JRA.
Woo (1994) reported that persistent disease activity disturbs growth in children 
with JCA through various mechanisms. Administration of growth hormone 
improved BMD parameters in patients with JCA. Kotaniemi (1997) estimated that 
the bone loss seems to develop with concurrent growth retardation at the spine, but 
without detectable growth retardation at the femoral neck in children with JCA.
Simon	and	associates	 (2002)	assessed	final	heights	 in	patients	with	JIA	on	
long-term	GCs,	and	revealed	that	chronic	inflammation	and	prednisone	therapy	
may adversely affect growth. Discontinuation of prednisone therapy led to catch-
up	growth	in	70%	of	children	and	to	the	possibility	to	achieve	greater	final	height.	
Valta and colleagues (2007) found normal growth in children with JIA over two 
years of disease duration and on systemic GC treatment for at least three months. 
Stagi and group (2010) revealed that children with JIA had delayed age at puberty 
onset in both boys and girls compared to the healthy Italian population.
3.3 PREVENTIVE OSTEOPOROSIS DRUG USE IN RHEUMATOID 
ARTHRITIS
A group under Soucy (2000) surveyed the practice pattern in GIO among 
Canadian rheumatologists via questionnaire. The initial strategy for prevention of 
OP was calcium and vitamin D3 (53%) in premenopausal women and HRT and 
calcium (29%) in postmenopausal women with RA. The pattern in the treatment 
of established OP was bisphosphonates (53%) in premenopausal women and 
bisphosphonates +/- HRT (53%) in postmenopausal women with RA.
Thiele and colleagues (2005) found that 63 per cent of patients with RA 
on GCs received OP treatment compared to 26% of those who were not on GC 
therapy. Solomon and group (2006) found that 48% received either a BMD test 
or a medication for OP. Patients with a prior fracture or diagnosis of OP and those 
receiving long-term GC treatment were much more likely to receive management.
Wall	and	Walker-Bone	(2008)	found	51	out	of	58	patients	with	RA	to	fulfil	criteria	
for bisphosphonates to receive OP treatment. Barrett-Connor and group (2009) in 
a longitudinal, multicenter cohort study of osteoporosis therapy in postmenopausal 
women in primary care including one rheumatology practice found that 63% of 
4994 patients used a single osteoporosis agent, mainly bishosphonate, and 934 
women (19%) were prescribed only calcium or vitamin D.
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Ledwich and Clarke (2009) evaluated patients with RA with long-term GC use 
in an urban setting practice, but only 38.9% of them received the recommended OP 
treatment according to the ACR guidelines. A group under Heberlein (2011) surveyed 
prophylaxis and treatment of OP in 101 out of 532 patients with RA who had had 
both a daily dose of GC 7.5 mg or less and in DXA measurements T-scores below 
-2.0 at any site. Among women, 41% of 83 menopausal and 17% of 6 premenopausal 
women received medication with both calcium/vitamin D and bisphosphonate. 
Correspondingly, 42% of 12 men received medication with both calcium/vitamin D 
and bisphosphonate. Gamez-Nava and associates (2013) explored OP drug use in 
520 patients with RA attending an outpatient rheumatology clinic during a period 
of three months. A total of 409 (79%) out of these 520 patients with RA had GCs, 
and in 21% of these patients the daily dose of GC was at least 7.5mg. All in all, 13% 
of the 520 RA patients and 14% of the 409 GC users received OP drugs, and 20% 
of the 520 RA patients received calcium and vitamin D supplements.
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4 AIMS OF THE STUDY
1. To obtain information on the development of OP, BMC and BMD in the 
lumbar spine and femoral neck and related factors in an inception cohort 
of patients with RA between 15 and 20 years from disease onset (I). 
2. To obtain information on BMC, projectional area and BMD development 
and related factors in premenopausal women with RA with or without 
GC treatment and in healthy controls followed up for two years (II). 
3. To obtain information on the development of OP, BMC and BMD and related 
factors in young adults with active or inactive JIA (III).
4. To obtain information on DMARD and GC use in patients with RA and JIA 
and possible predictive factors for OP, BMC and BMD development
5. To evaluate the implementation of pharmaceutical OP drug use in early 
rheumatoid arthritis in Finland during the years 2000-2007 (IV).
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MATERIALS AND METHODS
5 MATERIALS AND METHODS
5.1 DEVELOPMENT OF BONE MINERAL DENSITY AND THE 
OCCURRENCE OF OSTEOPOROSIS 15 TO 20 YEARS  
FROM DISEASE ONSET IN PATIENTS WITH  
RHEUMATOID ARTHRITIS (I)
Table	8	shows	the	flow	of	studies	I,	II	and	III.
A cohort of 108 patients with recent onset (<6 months) and RF-positive RA 
were followed up from 1973–75 at the Rheumatism Foundation Hospital (RFH) 
in Heinola, Finland (Kaarela 1985). The follow-up examinations took place at one, 
three, eight and 15 years from entry. A total of 74 patients with RF-positive and 
erosive	RA	attended	the	15-year	follow-up	in	1989,	when	for	the	first	time	BMD	
measurements were available. Viewed in retrospect they all met the 2010 ACR/
EULAR	classification	criteria	for	RA	(Kaarela	et	al.	2012).
Central BMDs were measured by DXA, Lunar DPX, Lunar Radiation Corporation, 
Madison, WI. The device had a wide angle fan beam technology, which meant a 
longer scanning time and a wider range of accuracy. The left hip could be scanned 
without further positioning the patient. Measurement sites were lumbar vertebrae 
L2–L4 in the spine and the left femoral neck. The precision of BMD measurements 
in adults was 1.0% in the lumbar spine and 1.8% in the femoral neck. To check for 
scanner-induced variability in longitudinal measurements, daily quality assurance 
measurements were made by a phantom provided by the manufacturer. Two women 
did not have BMD measured at the left hip due to endoprothesis in it. Two men 
and four women did not have BMD measured at the lumbar spine due to severe 
osteoarthrotic changes in the spine.
The use of DMARDs was registered. The cumulative dose of prednisolone 
from entry to 15 years of follow-up and between the 15- and 20-year check-ups 
was evaluated from patient registers simultaneously with determination of the 
erythrocyte sedimentation rate (ESR, mm/h) and C-reactive protein (CRP, mg/L).
The Larsen method was used to evaluate radiographs of hands and feet and to 
demonstrate the severity of RA at both 15- and 20-year follow-up visits. The joints to 
be interpreted were compared with standard series on a scale of 0 to 5. Joints with 
only soft tissue swelling or OP were assigned a Larsen grade of 0, joints with pre-
erosive changes or marked space narrowing grade 1, and joints after reconstructive 
surgery grade 5. Grades for the 1st to 5th metacarpophalangeal joints and wrists and 
the 2nd to 5th metatarsophalangeal joints (20) were summed to form a Larsen score 
of 0–100 (Larsen et al. 1977, Larsen 1995, Kaarela and Kautiainen 1997).
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Table 8. Chart of studies I, II, III
Variable Study I Study II Study III
Study type longitudinal longitudinal cross-
sectional
Lunar DPX
Lumbar vertebrae L2-L4
at 15 and 20 years 
from disease onset
at the start and at  
two years of follow-up*
Lunar DPX
Left femoral neck
at 15 and 20 years 
from disease onset
at the start and at  
two years of follow-up*
LUNAR Prodigy
Lumbar vertebrae L2-L4
x
LUNAR Prodigy
Femoral neck
x
Height at 15 and 20 years 
from disease onset
at the start and at  
two years of follow-up
x
Weight at 15 and 20 years 
from disease onset
at the start and at  
two years of follow-up
x
The use of disease-modifying
anti-rheumatic drugs
at 15 and 20 years 
from disease onset
at the start and at  
two years of follow-up
x
Larsen score of 0-100 at 15 and 20 years 
from disease onset
at the start and at  
two years of follow-up
Health Assessment 
Questionnairre
at 15 and 20 years 
from disease onset
at the start and at  
two years of follow-up
MDHAQ x
The number and location of
 large joint replacements
at 15 and 20 years 
from disease onset
The Ritchie articular index at the start and at  
two years of follow-up
Erythrocyte sedimentation rate at 15 and 20 years 
from disease onset
at the start and at  
two years of follow-up
x
C-Reactive protein at 15 and 20 years 
from disease onset
at the start and at  
two years of follow-up
x
 S-Calcium at the start of follow-up
S-Albumin at the start of follow-up
S-Phosphate at the start and at  
two years of follow-up
S-Parathormone at the start of follow-up
S-D-25 hydroxyvitamin D at the start of follow-up
Modified Disease Activity 
Score
DAS28
at the start and at  
two years of follow-up
HLAB27 factor and  
Antinuclear antibody
x
Pain Visual Analogue Scale x
*Double measurements, MDHAQ= multidimensional health assessment questionnaire
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Accordingly HAQ was registered. The HAQ includes questions on activities of 
daily living, 20 activities grouped into 8 categories. The highest score for each of 
these eight categories is summed (range 0–24) and divided by eight to yield a 
continuous scale (0–3). In HAQ scoring, 0 represents good functional ability and 3 
the poorest (Fries et al.1980). The number and location of large joint replacements 
were registered at the 20-year follow-up. Height and weight were measured at 
both visits.
5.2 CHANGES IN BONE MINERAL DENSITY IN 
PREMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS 
DURING A TWO-YEAR FOLLOW-UP (II)
Women attending wards in the RFH, Heinola, Finland, during the years 1991–95 were 
consecutively recruited for a two-year study of bone mass and RA. Premenopausal 
women (N=74) were eligible if they had RA and were menstruating regularly. 
Women who were pregnant, planning pregnancy, or taking oral contraceptives or 
other medications possibly affecting bone metabolism were ineligible. The use of 
DMARD and cumulative prednisolone (PRED) dose and calcium supplementation 
was evaluated.
Subjects were divided into two groups: 48 women with RA and with prednisolone, 
the RA with PRED group (mean age 37, SD 5 years), and 26 women with RA and 
without prednisolone, the RA without PRED group (mean age 37, SD 6 years). 
The control group (N=43) comprised age-matched, premenopausal, regularly 
menstruating healthy subjects recruited from the local population and hospital 
staff. Their mean age was 37 (SD 5) years.
Central BMDs were measured by DXA, Lunar DPX, Lunar Radiation Corporation, 
Madison, WI, the measurement sites being the three lumbar vertebrae L2–L4 in 
the spine and the left femoral neck as in study I. Furthermore, in comparing BMD 
changes over time, differences may be due to change in either BMC or projectional 
area or both. Thus, double measurements were made at all skeletal sites for all 
subjects at the start and at 24 months of follow-up.
The Larsen score of 0–100 was used to evaluate radiographs of hands and 
foreseed, and to demonstrate the severity of RA at both start and 2-year follow-
up visits (Larsen et al. 1977, Larsen 1995, Kaarela and Kautiainen 1997) and 
correspondingly HAQ was registered (Fries et al. 1980).
Height and weight were measured, and women with RA were examined for 
swollen and tender joints. The Ritchie articular index scores 53 joints as 26 joint 
groups, and each joint group was scored on a scale of 0–3. The Ritchie articular 
index ranges from 0 to 78, (26 times 3) (Ritchie et al. 1968).
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Blood samples were drawn for measurements for ESR, (mm/h), CRP, (mg/L), 
serum calcium (Ca, mmol/L), albumin (Prot, g/L), phosphate (Pi, mmol/L), 
parathormone (PTH, ng/L), and 25-hydroxyvitamin D (S-D-25, nmol/L) at the 
start of follow-up. We had no data on estrogen levels in our study subjects.
The	Modified	 Disease	 Activity	 Score	 (DAS28)	 is	 calculated	 by	 a	 complex	
mathematical formula, which includes the number of tender and swollen joints: 
shoulder, elbow, wrist, upper metacarpophalangeal and proximal interphalangeal 
and knee (a total of 28), ESR, and the patient’s ‘global assessment of global health’ 
(indicated by marking a 10 cm line between very good and very bad). A DAS28 
score greater than 5.1 implies active disease, less than 3.2 well controlled disease, 
and less than 2.6 remission (Prevoo et al. 1995).
5.3 BONE MINERAL CONTENT IN YOUNG ADULTS WITH 
ACTIVE OR INACTIVE JUVENILE IDIOPATHIC ARTHRITIS 
AND IN CONTROLS (III)
From	the	files	of	juvenile	patients	(aged	<16	years)	treated	at	the	RFH,	Heinola,	
Finland,	children	born	between	1976	and	1980	were	 identified,	altogether	587.	
Data on patients who had been diagnosed as suffering from JA were collected; 
189 patients were thus excluded as having some other diagnosis than JA. From 
among the remaining 398 patients those in whom JA was diagnosed at the RFH 
were collected. This led to the exclusion of a further 211 patients as their treatment 
had been initiated elsewhere.
The comparability of the study group and the withdrawal group was analyzed and 
no difference was found in the distribution of diagnoses and clinical characteristics. 
The only difference between the groups was in the proposition of men, 28% in the 
study group, and 43% in the remainder.
There were thus 187 patients with early untreated JIA whose diagnosis was 
made at the RFH and treatment initiated there. Four had Down’s syndrome and 
could not attend due to social and educational problems. Two patients had died 
due	to	accidental	causes.	All	 these	patients	were	reclassified	using	JIA	(Petty	et	
al. 1998) criteria. Thus 181 patients were invited by mail to take part in the study. 
There were 20 refusals, 12 could not be reached, 26 could not make time for the 
visit	and	three	did	not	fulfil	the	JIA	criteria.
Altogether, 120 patients (68%) participated, but 116 (33 men and 83 women) 
comprised	the	final	study	group,	as	four	patients	were	pregnant.	The	mean	age	
was 23 (SD 1.8) years for men and 23 (SD 1.5) for women. Seventy-four out of the 
116 (26 men and 48 women) had oligoarthritis and 42 (seven men and 35 women) 
polyarthritis subset of JIA. Fifteen out of 74 patients with oligoarthritis at onset 
were	classified	as	having	the	extended	form.
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The JIA patients were further divided into two groups: those having active disease 
(the JIA-active group, N=73) and those in remission (the JIA-inactive group, N=43). 
A patient was considered to be in remission at check-up if ESR was < 20 mm/h, 
morning stiffness lasted < 15 minutes, there were no tender or swollen joints, and 
the patient had been off DMARDs, or GCs for at least the past two years. The 
control group comprised 21 men and 47 women between 21 and 26 years of age 
gathered from the local population. The mean age was 23 (SD 1.7) years for men 
and 23 (SD 1.4) years for women.
BMC measurement was carried out at the lumbar spine and the proximal femur, 
using LUNAR Prodigy, Lunar Radiation Corporation, Madison WI. This is a DXA-
absorptiometry-using digital beam device providing shorter scanning time and 
better accuracy than Lunar DPX. Both hips could be scanned simultaneously without 
further positioning of the patient. The software of the absorptiometry guides the 
operator during the examination to follow the examination protocol. The precision 
of BMD measurements in adults was 0.10% [95%CI: 0.02 to 0.04] in the lumbar 
spine and 1.21% [95%CI: 0.02 to 0.04] in the femoral neck.
Height, weight, diagnosis, time from diagnosis to check-up, and disease duration, 
ESR (mm/h), CRP (mg/L), HLAB27-factor, antinuclear antibody (ANA), and 
DMARD and prednisolone use were evaluated.
Pain was evaluated by a 10 cm Visual Analogue Scale (VAS). The scoring was 
0, representing no pain, to 100, representing pain as severe as could be endured 
(Huskisson 1974).
The multidimensional health assessment questionnaire (MDHAQ) includes 10 
activities, one from each eight category of the HAQ plus two items concerning 
advanced function, and three items on psychological stress; pain, global and fatigue 
VAS. Scoring in MDHAQ was from 0 to 3, 0 representing good functional ability 
and 3 the poorest (Pincus et al.1999).
5.4 USE OF OSTEOPOROSIS DRUGS IN PATIENTS WITH 
RECENT-ONSET RHEUMATOID ARTHRITIS IN FINLAND (IV)
Finland provides general health insurance covering the entire population. The Social 
Insurance Institution (SII) reimburses 42% of the costs of medication prescribed by 
a doctor. Patients with certain chronic and severe diseases such as RA are entitled 
to a special reimbursement rate (72% or 100%) to defray drug costs. To establish 
entitlement,	a	patient	must	file	a	doctor’s	certificate	based	on	clinical	examination	
by a rheumatologist describing the appropriate diagnostic procedure, giving the 
ICD-10 code, and providing a treatment plan according to good clinical practice. 
The	International	Classification	of	Diseases	(ICD)	and	its	10th version have been 
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designed to promote international comparability in the collection, processing and 
classification	and	presentation	of	mortality	statistics	and	medical	files.	The	ICD-
10 codes M05, seropositive RA and M06 seronegative RA were used to identify 
patients. Codes M05 and M06 are used by rheumatologists in early RA and these 
codes are required for entitlement to the higher reimbursement granted by the SII.
Reimbursement decisions were recorded in a nation-wide register in 2000-
2007. From this register those RA patients were obtained who during the period 
from	1.1.2000	to	31.12.2007	were	for	the	first	time	granted	special	reimbursement	
for medication for RA (DMARDs and GCs).
The SII also keeps a prescription register which collects and stores data on 
purchases of all reimbursed drugs, including the date of purchase, the amount of 
medication	and	the	Anatomical	Therapeutic	Chemical	classification	(ATC)	code	of	
the drug. The ATC codes of the drugs used were: M05BAO4, M05BB03, M05BB04, 
M05BA06, M05BA01, M05BA03, M05BA03, M05BA08, H05BA01, G03XC01, 
H05AA02, H05AA03, M05BX03, A11CC05, A11CC01, A12AA04, A12AA02, 
A12AA12, A12AX, H02AB06, H02AB07, H02AB01, H02AB08, H02AB09, 
H02BX01.
By means of these registers, data on the OP medication which index patients with 
RA had purchased was obtained. The focus was exclusively on medication during 
the	first	treatment	year.	Information	for	30	days	before	and	up	to	365	days	after	
the	index	day	was	included	to	take	into	account	medications	bought	after	the	first	
doctor visit but before the reimbursement decision. Data on four two-year periods: 
2000–1, 2002–3, 2004–5, and 2006–7 were analysed.
In Finland, preparations containing calcium and vitamin D, which are also 
used in OP preventions, were available over the counter; data on their overall use 
could thus not be obtained. Many preparations, however, were included in the 
reimbursement system and reimbursed (42%) to the patient, if purchased upon 
doctor’s prescription. Data on these purchases were gathered. Some GC preparations 
were temporarily excluded from the reimbursement system during the years of 
2006 and 2007, which caused some bias. Consequently, GC use only from 2000 
to 2005 inclusive was analysed. HRT was not included, as it is indicated mainly 
for reasons other than OP per se. The prescription register does not collect data on 
medications used in hospitals and institutions.
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5.5 STATISTICAL ANALYSIS
Results are expressed as mean or median, SD or interquartile range (IQR), and 95 per 
cent	confidence	intervals	(95%CI).	Statistical	comparison	between	groups	was	made	
using either t-test or permutation (Monte Carlo P-value) test or Chi-square test.
Analysis of covariance (ANCOVA) was used to analyse BMC between groups, 
followed by a Sidak test. The normality of variables was evaluated by Shapiro-Wilk 
statistics.	Correlation	coefficients	were	calculated	by	the	Spearman	method.
Regression analyses with biased corrected bootstrapping (10,000 replications) 
confidence	intervals	were	used	to	model	the	relationship	between	BMD	change	and	
predictor variables. A generalized linear model with the binomial family, log link, 
was used to produce the adjusted relative risk (RR).
Repeated measures were analyzed using generalized linear mixed models. Fixed 
effects were group, time, and time-group interaction, and the covariate was weight. 
Subject effects were assumed to be random. This is the most suitable technique for 
estimating rates of change, allowing for the correlation structure (unstructured) of 
repeated measures data.
Associations of BMC with explanatory variables were analyzed using robust 
regression.	The	α	level	was	set	at	0.05	for	all	tests.	
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6 RESULTS
6.1 BONE MINERAL DENSITY IN PATIENTS WITH RA  
(STUDIES I, II)
In study I at the 15-year check-up 18 (31%) out of 59 patients had OP and 32 (54%) 
patients	were	osteopenic.	After	the	subsequent	five	years	the	mean	Z-score	increased	
0.45 at the lumbar spine and the mean T-score decreased 0.20 at the femoral neck. 
Correspondingly, the mean change in BMD was 0.01 g/cm² in the lumabr spine 
and	0.02	g/cm²	in	the	femoral	neck	during	the	five	years	of	follow-up.bv	
In study II, assessing BMD change in 74 patients with RA, the patients in the RA 
with PRED group had lower BMD values than those in the RA without PRED group 
at commencement of follow-up. The mean weight-adjusted BMD percentage change 
in the lumbar spine up to two years was -1.5% in the RA with PRED group, +0.6% in 
the	RA	without	PRED	group	and	-0.6%	among	the	controls;	a	significant	difference	
(P=0.030) was found between the RA groups. Correspondingly, the mean weight-
adjusted BMD percentage change in the femoral neck to two years was -2.6% in the 
RA with PRED group, +0.4% in the RA without PRED group and -0.9% among the 
controls,	the	difference	between	the	RA	groups	being	again	significant	(P=0.049).
However, when BMD is expressed as BMC and projectional area there was no 
statistically	significant	difference	between	the	three	groups	in	change	in	BMC	or	
projectional area in the lumbar spine or femoral neck.
The mean BMC percentage change in the lumbar spine was -2.2% in the RA with 
PRED group (P =0.003), +0.0 in the RA without PRED group and -0.6% in the 
control group. Correspondingly, the mean BMC percentage change in the femoral 
neck was -1.9% (P=0.006), -0.4% and -0.8%, respectively, Table 9.
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Table 9. Bone characteristics at baseline and change up to two years in controls  
and patients with RA in study II.
Bone 
characteristic
Baseline Change to 2 years P-value 
Between 
groups
(multiple 
comparison)‡
Controls
Mean
(SE)†
RA
Mean
(SE)
RA with 
PRED
Mean
(SE)
Controls
Mean
(95%CI)
RA
Mean
(95%CI)
RA with 
PRED
Mean
(95%
CI)
Lumbar spine
BMD, g/cm² 1.22
(0.02)
1.19
(0.03)
1.11
(0.02)
-0.01
(-0.02 to 
0.00)
0.01
(-0.01 to 
0.02)
-0.02
(-0.03 to 
-0.01)
0.030
(RA/GC)
BMC, g 52.7
(1.2)
51.4
(1.6)
48.9
(1.2)
-0.30
(-1.05 to 
0.45)
0.01
(-0.93 to 
0.95)
-1.07
(-1.78 to 
-0.37)
0.14
Area, cm² 42.9
(0.5)
42.9
(0.7)
43.6
(0.5)
-0.03
(-0.40 to 
0.34)
-0.20
(-0.65 to 
0.25)
-0.25
(-0.59 to 
0.09)
0.67
Femoral neck
BMD, g/cm² 0.96
(0.02)
0.91
(0.02)
0.88
(0.02)
-0.01
(-0.02 to 
0.00)
0.00
(-0.01 to 
0.02)
-0.02
(-0.04 to 
-0.01)
0.049
(RA/GC)
BMC, g 4.60
(0.09)
4.43
(0.12)
4.20
(0.09)
-0.03
(-0.10 to 
0.03)
-0.02
(-0.09 to 
0.06)
-0.08
(-0.13 to 
-0.02)
0.37
Area, cm² 4.78
(0.05)
4.81
(0.06)
4.77
(0.04)
0.01
(-0.07 to 
0.10)
0.00
(-0.08 to 
0.13)
-0.02
(-0.10 to 
0.05)
0.70
† Mixed model with REML estimation, weight at baseline as covariate.
‡ Statistically significant difference (p<0.05) between groups detected by Sidak’s test.
RA= rheumatoid arthritis, PRED= prednisolone, BMD= bone mineral density, BMC= bone mineral 
content, GC= glucocorticosteroid
6.2 BONE MINERAL CONTENT IN YOUNG ADULTS WITH JIA 
(STUDY III)
The mean BMC in the femoral neck was 5.76 (SD 0.21) g for men and 4.74 (SD 
0.10) g for women in the JIA-active group; 5.84 (SD 0.23) g for men and 4.59 (SD 
0.06) g for women in the JIA-inactive group; and 6.65 (SD 0.20) g for men and 
4.78 (SD 0.07) g for women in controls.
Both JIA groups had lower BMC values in the femoral neck than the controls 
(P <0.001). In comparing BMC values in the femoral neck in men and women 
with	JIA,	a	significant	difference	was	found	among	men	(P=0.006).	There	was	no	
significant	difference	in	weight-,	height-	and	sex-adjusted	BMC	values	in	the	lumbar	
spine	between	JIA	groups	and	controls	(P=0.33),	nor	was	there	any	significant	
difference between men and women (P=0.43 and 0.59, respectively).
51
The	male	and	female	JIA	patients	had	significantly	lower	weight-	and	height-
adjusted BMD values in the femoral neck than the controls, but according to T-score 
< -2.5, only three [2.6%(95%CI: 0.5 to 7.4)] out of 116 patients with JIA had OP.
6.3 USE OF DMARDS AND GLUCOCORTICOIDS  
(STUDY I, II, III)
In	study	I,	at	the	first	visit	during	the	years	1973–1975,	90%	of	patients	had	received	
treatment initially with gold sodium thiomalate, hydroxychloroquine, penicillamine 
and/ or prednisolone or their combinations. Sulfasalazine was introduced in the 
treatment regimen after 1982. Only six patients used methotrexate periodically 
during the years 1991–96 (Jäntti et al. 2002). GC use among patients with RA 
from entry to the 15-year-, and between the 15- and 20-year follow-ups is set out 
in Table 10.
Table 10. Glucocorticosteroid use from entry to the 15-year- and between the15- and 20-year follow-ups 
in 59 patients with RA in study I.
Variable men women
Median (IQR) cumulative dose of prednisolone  
from entry to 15-year follow-up, g
8.0
(0.00 , 15)
1.0
(1 , 9)
Median (IQR) cumulative dose of prednisolone  
from 15-year to 20-year follow-up, g
0.5
(0.00 , 6.12)
1.0
(0.00 , 6.75)
RA= rheumatoid arthritis, IQR= interquartile range
In study II, treatment of RA patients consisted mainly of single DMARDs: 73% in 
both the RA without PRED group and the RA with PRED group. None of the patients 
in the RA without PRED group had previous corticosteroid treatment. The median 
(IQR) cumulative dose of prednisolone before the outset was 4.0 (0.5 , 9.0) g and 
the median duration of previous GC use was two years in the RA with PRED group. 
The median (IQR) cumulative dose of prednisolone during the two-year follow-up 
was 3.6 (1.5 , 4.5) g in the RA with PRED group. There was no difference in serum 
Ca, Pi and PTH values between the two RA groups.
In study III, patients in both JIA groups used DMARDs mainly as single therapy.
Table 11 shows DMARD and glucocorticoid use among JIA patients during their 
disease course.
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Table 11. Number of glucocorticosteroid users and median time on both disease-modifying  
anti-rheumatic drug and glucocorticosteroid in 116 patients with JIA in study III.
Variable JIA active group
N=73
JIA inactive group
N=43
Number and percentage of GC users 35*
(48)
7
(16) 
Median (IQR) time on GC use, years 4.8
(0.7 , 8.8)
1.1
(0.7 , 3.5)
Median (IQR) time on on DMARDs, years 13.3
(6.6 , 19.9)
3.4
(2.1 , 8.8)
*P<0.001
GC= glucocorticosteroid, DMARD= disease-modifying anti-rheumatic drug, IQR= interquartile 
range, JIA= juvenile idiopathic arthritis
6.4 DISEASE SEVERITY AND REMISSION  
(STUDIES I, II, III)
In study I at the 15-year follow-up, the median (IQR) ESR was 32 (18 , 48) in 
men and 20 (11 , 41) in women. Between the 15- and 20-year follow-up visits the 
median difference in ESR was 2 [95%CI: -6 to 2], (P=0.32). Correspondingly, the 
median (IQR) CRP was 14 (3 , 63) in men and 2 (2 , 24) in women. Between the 
two follow-ups the median difference in CRP was 2 [95%CI: -2 to 4], (P=0.53). 
Furthermore, at the 15-year follow-up the median (IQR) Larsen score of 0-100 was 
44 (32 , 62) in men and 33 (17 , 61) in women. Between the 15- and 20-year follow-
up visits the median difference in median Larsen score of 0-100 was 6 [95%CI: 4 
to 6] points, (P<0.001).
In study II at the start of follow-up the mean DAS28 score was 3.8 in the RA 
without PRED group and 4.4 in the RA with PRED group. During the two-year 
follow-up the mean DAS28 score decreased by 0.22 (95%CI: -0.67 to -0.22) in the 
RA with PRED group and by 0.30 [95%CI: -0.91 to 0.32] in the RA without PRED 
group,	but	the	decrease	was	not	significant.	Correspondingly,	 the	median	(IQR)	
Larsen score of 0–100 at the start of follow-up was 16 (7 , 34) in RA without PRED 
and 31 (7 , 64) in the RA with PRED group. Furthermore, during the two-year study 
period the median Larsen score of 0–100 increased by 8 points, [95%CI: 5–9] in 
the RA with PRED group and by 3 points, [95%CI: 2–8] in the RA without PRED 
group (P=0.074).
In study III 18 out of 33 (55%) men and 25 out of 83 (30%) women were in 
remission (P= 0.014). The median (IQR) ESR was 3 (2 , 5) in men and 9 (5 , 13) 
in women and the median (IQR) CRP was 2 (2 , 3) and 2 (2 , 3), respectively. The 
mean MDHAQ FN-score was 0.13 (SD 0.30) in men and 0.15 (SD 0.30) in women. 
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6.5 PREDICTIVE FACTORS FOR BONE MINERAL DENSITY 
(STUDIES I, II, III)
Concerning the clinical data in study I none of the explanatory variables: sex, age, 
ESR, HAQ, Larsen score, and cumulative prednisolone dose between 15–20 years 
from	disease	onset,	was	found	to	be	a	significant	predictor	of	BMD	change	at	the	
lumbar spine and femoral neck in the 15- to 20-year check-ups.
Furthermore, concerning the clinical data in study II none of the explanatory 
variables: age, ESR, CRP, number of tender or swollen joints, HAQ, Larsen score, 
and	cumulative	prednisolone	dose	was	found	to	be	a	significant	predictor	of	BMD	
change	at	the	lumbar	spine	or	femoral	neck.	Only	weight	emerged	as	a	significant	
predictor of BMD change, Table 12.
Table 12. Main results of multivariate analyses modeling the relationship between bone mineral density 
changes and clinical variables in 74 patients with RA in study II
Explanatory variables Regression model
Lumbar spine Femoral neck
β † (95% CI ‡) P-value β † (95% CI ‡) P-value
Age, years 0.06 
(-0.43 to 0.63)
0.81 -0.04 
(-0.51 to 0.55)
0.87
Weight, Kg 0.74 
(0.29 to 1.25)
0.003 0.65 
(0.23 to 1.14)
0.004
Duration of disease, years 0.11 
(-0.38 to 0.66)
0.63 -0.40 
(-0.87 to 0.12)
0.10
ESR, mm / h 0.08 
(-0.25 to 0.06)
0.27 -0.09 
(-0.23 to 0.03)
0.34
CRP, mg/L -0.08 
(-0.25 to 0.09)
0.32 -0.09 
(-0.23 to 0.03)
0.10
Number of swollen joints -0.15 
(-0.82 to 0.54)
0.66 -0.16 
(-0.69 to 0.38)
0.54
Number of tender joints 0.03 
(-0.62 to 0.66)
0.91 -0.16 
(-0.66 to 0.40)
0.50
Health Assessment Questionnaire -4.1 
(-13.0 to 3.5)
0.34 -2.0 
(-9.19 to 3.81)
0.54
Cumulative prednisolone dose, g -0.03 
(-0.28 to 0.27)
0.81 -0.04 
(-0.51 to 0.55)
0.48
Constant 74.9 64.5
† Coefficients multiplied by 100.
‡ 95% confidence interval obtained by bias corrected bootstrapping (10 000 replication). 
RA = rheumatoid arthritis
ESR = erythrocyte sedimentation rate
CRP = C-reactive protein
Study III showed in regression analysis that among men, use of GCs and weight 
were	significantly	associated	with	BMC	in	the	femoral	neck.	Among	women,	use	
of	GCs,	weight	and	also	height	were	associated	statistically	significantly	with	BMC	
in the femoral neck, and among women GC use and height were also associated 
with BMC in the lumbar spine.
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6.6 USE OF OSTEOPOROSIS DRUGS IN PATIENTS WITH 
RECENT-ONSET RA
All	 officially	 known	 14	 878	 incident	 cases	 of	RA	 in	 Finland	 from	 1.1.2000	 to	
31.12.2007	were	identified.	Of	these,	10	119	(68%)	were	female	and	4739	(32%)	
male. The male-female ratio was 1:2.1. Mean age, percentage of MTX, GC, calcium 
and vitamin D users are shown in Table 13.
Table 13. Mean age, and percentages of methotrexate, glucocorticosteroid, and calcium and vitamin D 
users during the first drug treatment year in 14 878 cases of early RA in study IV.
Variable Men
N=4739
Women
N=10 119
Mean age (SD),
years
56
(15)
57*
(14)
Percentage of MTX users 56 58
Percentage of GC usersª 52 49
Percentage of calcium and vitamin D users 
by a doctor´s prescriptionª
19 29
*55% of the women were 55 years of age or older
ªDuring the period 2000 to 2005 inclusive
MTX= methotrexate, GC=glucocorticosteroid, RA= rheumatoid arthritis, SD= standard deviation
A total of 1351 (9%) patients with RA (11% of females and 5% of males) had purchased 
OP	drugs	during	the	first	year	after	commencement	of	antirheumatic	treatment.	
Women were more likely to use OP medication. Consequently, the age-adjusted 
relative risk of purchase was 2.60 (95% CI 2.26 to 2.99) for women compared to men.
Bisphosphonates constituted the bulk of purchases. Calcitonin was used by 7%. 
Purchases	of	SERMs	and	PTHan	were	almost	negligible.	During	the	first	year,	26%	
of patients (29% of females and 19% of males) received calcium and vitamin D 
supplementation on doctor’s prescription.
The use of OP drugs during the years 2006 – 2007 increased over time compared 
to 2000–2001. RR (95% CI) for purchase was 1.62 (1.38 to 1.92) in women and 
2.10 (1.34 to 3.30) in men. During the year 2006, 12% of women and 5% of men 
bought OP medication within 365 days of the index day. The highest proportion 
was found for the age groups 75 to 79 years.
Patients on OP medication received MTX marginally more often (in women 
61% and in men 57%) than other DMARDs. Of RA patients who took GCs, 38% of 
women and 24% of men received concomitant calcium and vitamin D preparations 
by prescription during the same year, whereas the corresponding percentages for 
patients without GCs were 21% and 13%.
Of GC users, OP drugs were prescribed to 14% of women and 6% of men. In 
contrast, 8% of females and 3% of males not taking GCs received OP medication. 
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In multiple regression analysis, GC use was determined as a “risk factor” for 
OP medication: its risk ratio (RR) was 1.45 (95% CI 1.31 – 1.61), whereas female 
gender had an RR of 2.54 (95% CI 2.21 – 2.91) and higher age had an RR of 1.060 
(95% CI 1.057 – 1.065).
6.7 SUMMARY OF THE RESULTS
In assessing BMD at 15 years from disease onset in an inception cohort of RF-
positive RA patients, it was found that eighteen out of 59 (31%) patients had OP. 
However, the decreases in central bone mineral in this patient group were of low 
degree	and	after	the	subsequent	five	years	no	essential	change	in	central	BMD	was	
found. None of the explanatory variables: sex, age, ESR, HAQ, Larsen score, and 
cumulative prednisolone dose between 15–20 years from disease onset, proved to 
be	a	significant	predictor	of	BMD	change	at	the	lumbar	spine	and	femoral	neck	
from 15- to 20-year check-ups (I).
 In assessment of BMC and BMD development in premenopausal, regularly 
cycling RA patients with and without GCs and in controls, it was found that RA 
patients with GCs had lower BMD values than those without GCs at commencement 
of	follow-up.	Furthermore,	the	mean	BMD	decreased	significantly	in	both	lumbar	
spine (P=0.002) and femoral neck (P<0.001) only in the RA patients with GCs 
during	the	2-year	follow-up.	However,	there	was	no	statistically	significant	difference	
between the three groups in change in BMC or projectional area in the lumbar spine 
or femoral neck. BMD is expressed as BMC per projectional area. Only weight was 
found	to	be	a	significant	predictor	of	BMD	change	(II).
Assessment of BMC and BMD development in young adults with JIA and controls 
assumed to have reached their peak bone mass, showed that three (2.6%) out of 116 
patients with JIA had OP. The male and female JIA patients had lower weight- and 
height-adjusted BMD values in the femoral neck than the controls. Dividing the 
patients into two groups, those with active and those with inactive JIA, both groups 
had lower BMC values in the femoral neck than the controls (P<0.001). Comparing 
BMC values in the femoral neck in both men and women with JIA a difference 
was found only among men (P= 0.006). Among men, use of GCs and weight were 
significantly	associated	with	BMC	in	the	femoral	neck.	Among	women,	use	of	GCs,	
weight	and	also	height	were	associated	statistically	significantly	with	BMC	in	the	
femoral neck, and among women GC use and height were also associated with 
BMC in the lumbar spine (III).
A total of 14 878 incident cases of RA were studied. Out of this total, 1351 (9%) 
patients with RA had purchased OP drugs, mainly bisphosphonates, during the 
first	year	after	commencement	of	antirheumatic	treatment.	Of	GC	users,	14%	of	
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women and 6% of men were prescribed OP drugs. In addition, 8% of females and 
3% of males not taking GCs received OP medication. Women were more prone to 
use OP medication. Of the RA patients who took GCs, 38% of women and 24% 
of men received concomitant calcium and vitamin D preparations by prescription 
during the same year, whereas the corresponding percentages for patients without 
GCs were 21% and 13%. (IV).
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7 DISCUSSION
7.1 THE STUDY POPULATIONS
Study I comprised RF-positive and erosive RA patients from the Heinola community-
based inception cohort. Follow-up initiated at the RFH in 1973-75 involved 108 
patients with age 16 years or more, swelling in at least one joint, and duration 
of complaint not more than six months (Kaarela 1985). These community-based 
patients have been evaluated thereafter at 1, 3, 8, 15, and 20 years from entry (Nissilä 
et al. 1983, Kaarela 1985, Kaarela et al. 1993, Jäntti et al. 1999, 2001, 2002, Jäntti 
2004, Palm et al. 2002). Treatment with parenteral gold and/or hydroxychloroquine 
did not essentially change the natural course of RA, and the outcomes of these 
patients were mainly severe diseases (Jäntti et al. 2002). According to 20-year 
follow-up of the subjects the limitation is the low number of subjects and men in 
study I.
In study II the patients represented inhabitants of the Päijät-Häme district, 
as the RFH during the years 1991–95 served as the principal site for treatment of 
patients with RA covering the responsibility area of Päijät-Häme Central Hospital. 
Postmenopausal bone loss is a strong confounding element in efforts to identify other 
factors underlying axial bone loss among women, and therefore premenopausal 
women with regular cycles were chosen to participate.
Patients with JIA in study III represented children whose diagnosis was made 
and treatment started at the RFH. Their disease course and treatment was sought 
in	their	files	until	young	adulthood.	Furthermore,	being	in	young	adulthood	they	
were presumed to have reached their peak bone mass.
7.2 DISEASE SEVERITY AND REMISSION
In the control of disease severity in RA, bone destruction (erosion) seems to be the 
most important long term variable (Larsen 1995, Kaarela and Kautiainen 1997, Scott 
et al. 2000, Jäntti et al. 2002). Indeed, the Larsen score of 0–100 in patients with 
RA increased over time in studies I and II, emphasizing the inevitable course of RA.
 The median HAQ scores in patients with RA were rather low in both studies I 
and II. Sokka and associates (2003) compared HAQ scores between patients with 
RA and a community population in Finland, and found RA to be associated with 
a >7-fold risk of disability compared with that in the general population of adults. 
Further, the HAQ scores increased with age in patients with RA and in controls. 
58
DISCUSSION
Hakala and colleagues (1994) found that patients´self-reported functional ability 
in	RA	reflected	their	physical	impairment	due	to	their	arthritic	joint	disease.	Wolfe	
(2000) held that HAQ scores at group level seemed to have a stable course, but 
there was also major individual variation over time, scores tended to be high at 
disease onset rather than gradually increasing, and the increase over time was 
0.03 units/year.
The variables of disease activity ESR and CRP were stable in study I. The DAS28 
score	decreased	in	both	RA	groups	in	study	II,	but	not	significantly.	There	were	
more men in remission than women in study III. In all, these outcomes give an 
overview of disease course and disease activity as elegantly discussed by Buchbinder 
and colleagues (1995). The chosen remission criteria seemed to be clinically 
comprehensive in study III, while there is no general agreement on remission 
criteria in JIA (Adib et al. 2005).
7.3 MEASUREMENT OF BONE MINERAL CONTENT AND BONE 
MINERAL DENSITY
The software implementations of absorptiometry devices assume an average fat-
to-lean body mass ratio and different machines therefore give different results in 
BMC at the same measurement site (Pocock et al. 1992). These results are however 
in close correlation with each other (Genant et al. 1994). Furthermore, at different 
measurement sites of bone there are variable proportions of cancellous and cortical 
bone. Thus, measurements of BMD at several sites give a better overview of BMD 
(El Maghraoui et al. 2006). Variation in accuracy in DXA measurements is partly 
explained by variation in soft tissue, shape and size of bone at the measurement site 
(Svendsen et al. 1993). With this in mind a group under Engvall (2011) determined 
whether low-dose prednisolone affects body composition and BMD measurement 
in	patients	with	RA.	Those	with	prednisolone	treatment	had	significantly	higher	
fat mass than those without, but there was no association between prednisolone 
treatment and muscle mass or BMD. It is thus important to use appropriate reference 
ranges provided by the manufacturer to avoid technical discordance when the 
average	BMD	of	the	normative	group	used	to	calculate	the	T	score	is	significantly	
different from the average value found for the whole population. In studies I, II 
(Lunar DPX) and III (Lunar Prodigy) ‘the Finland AP spine and Femur reference 
population 20–45 years’ was applied and provided by the manufacturerer.
The presence of osteophytes and disc space narrowing in degenerative disc 
disease	in	the	lumbar	spine	and	aortic	calcification	may	increase	BMD	artificially	
in PA measurement of the lumbar spine (Drinka et al. 1992, Frye et al. 1992, Watts 
2004, El Maghraoui et al. 2006). The collapse of lumbar vertebrae may substantially 
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increase BMC and BMD values (Ryan et al. 1992). Thus, four out of 49 women and 
two out of 10 men did not have BMD reliably measured at the lumbar spine due 
to severe osteoarthrotic changes in study I.
The	reproducibility	(precision	error)	is	expressed	by	the	coefficient	of	variation	
(CV). This depends on quality assurance of the BMD measurement process. To 
ensure	at	least	95%	confidence	that	a	measured	BMD	change	is	a	real	effect,	the	
change must exceed the precision error 2.8 times (Bonnick et al. 2001). This is also 
termed	the	least	significant	change	(LSC,	Glüer	1999,	Ravaud	et	al.	1999).	
The protocol of BMD measurement was monitored and obeyed as well as possible 
in studies I, II and III. Reproducibility was 1.0% for the lumbar spine and 1.8% for 
the femoral neck in studies I, II (Lunar DPX), and 0.10%, and 1.21% (Lunar Prodigy) 
in study III, respectively. Correspondingly, the LSC was 2.8% for the lumbar spine 
and 5.0% for the femoral neck in studies I and II and 0.28% and 3.4% in study III, 
respectively. Furthermore, double measurements were made in study II.
In measuring BMD in a subject over time there is a need to distinguish between 
a	true	change	in	BMD	and	a	random	fluctuation	in	BMD	related	to	variability	in	
the measurement procedure, scanner-induced variability or other unpredictable 
sources such as weight change in the object (Sievänen et al. 1994, Ngyen et al. 
2000, Phillipov et al. 2001, El Maghraoui et al. 2007, Rajamanohara et al. 2011). 
Scanner-induced variability occurs in daily performance and in silently degrading 
scanner performance in the longterm. It is due to inhomogeneity of the scanners’ 
X-ray	beam	intensity	over	the	tabletop,	and	changes	in	internal	filtration	(Sievänen	
et al. 1994). Phillipov and associates (2001) revealed that the measurement of BMD 
will present greater variation as the number of operators is increased. A group 
under Rajamanohara (2011) examined the effect of weight and weight change on 
the long-term precision of spine and hip BMD in 64 postmenopausal women over 
a 10-year period. Long-term precision errors were 50% larger than short-term 
errors. Weight changes up to 5 kg had little effect on precision. Furthermore, El 
Maghraoui and colleauges (2005) stated that at group level the reproducibility of 
BMD measurements by DXA in patients with chronic rheumatic diseases expressed 
by different means is good. This reproducibility seems to be independent of age 
and clinical status and the measurement of both hips improves the reproducibility. 
Both hips were measured in study III and the same operators performed the BMD 
measurements in studies I, II and III.
In comparison of BMD changes between study groups over time it is necessary to 
distinguish between a true change in BMC and projectional area. This was explored 
in study II when changes in BMD, BMC and projectional area were assessed between 
three	groups.	In	fact	there	was	no	statistically	significant	difference	between	the	three	
groups in the change in BMC or projectional area in the lumbar spine or femoral 
neck. Comparing changes in BMD alone between the three groups a statistically 
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significant	difference	was	found.	This	is	in	line	with	Heaney´s	editorial	statement	
in 2005, ‘all densitometric comparisons between groups should be based on BMC 
and area measurements’.
Due to the LSC the time interval between two measurements in the same patient 
must be long enough, about two years, to allow changes in BMD to take place 
(Philippov	et	al.	2001).	In	study	I	the	time	lapse	was	five	years	and	in	study	II	two	
years. 
7.4 DMARD AND GLUCOCORTICOIDS
It	is	difficult	to	evaluate	the	impact	of	DMARDs	on	BMD	changes	in	patients	with	
RA and JIA. Bias by treatment indication should be considered when RA patients 
with a severer disease course could have been treated aggressively. MTX was used 
in various combinations in studies II, III. Buckley and associates (1997) in a 3-year 
follow-up study observed that low-dose MTX was not associated with change in 
BMD in the lumbar spine or femoral neck treated without prednisone at least 5 mg 
per day. Combined treatment with MTX and prednisone was associated with greater 
bone loss in the lumbar spine. Di Munno and group (2004) found no negative effect 
of low-dose MTX on BMD in women with RA. A group under Tascioglu (2003) 
found that low-dose MTX had no negative effect on BMD in premenopausal RA 
patients. Goes and group (2013) revealed that the addition of 10 mg prednisone 
daily to a MTX-based tight control strategy did not lead to bone loss in early RA 
patients on bisphosphonates. Biologics seem to stop systemic bone loss in patients 
with rheumatic diseases (Confavreux and Chapurlat 2011, Krieckaert et al. 2013). Use 
of biologics was scant according to mean person years of DMARD use in study III.
HRT was not allowed in study II. No reliable information was available on 
HRT	use	in	study	I.	Forsblad	and	group	(2003)	showed	that	HRT	has	a	beneficial	
effect on BMD in the lumbar spine and total hip in women with long-lasting RA. 
No reliable data on calcium and vitamin D substitution was available in study I.
Vitamin D, 25-hydroxyvitamin D levels were measured only in study II and there 
was no difference in serum Ca, Pi, and PTH values between the two RA groups. 
Vitamin	D	deficiency	seems	to	be	prevalent	among	youngsters	and	adults	(Chapuy	
et	al.	1997,	Lehtonen-Veromaa	et	al.	2002).	Vitamin	D	deficiency	also	affects	bone	
mass, inducing secondary hyperparathyroidism (Outila et al. 2001, Lips 2001). The 
international problem in standardization of 25-hydroxyvitamin D assays may bias 
personal analysis results (Sempos et al. 2012).
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7.5 SENSITIVITY OF THE SICKNESS INSURANCE REGISTERS
The	advantage	in	study	IV	was	the	availability	of	nationwide	official	register	data.	
The	case	definition	was	based	on	eligibility	for	special	reimbursement	for	DMARDs	
used in the treatment of RA, that is, a clinical diagnosis of RA by a rheumatologist 
and the need to initiate antirheumatic medication. No data were available on the 
fulfilment	of	the	ACR	classification	criteria	for	RA,	but	the	use	of	antirheumatic	
medication can be regarded as highly indicative for an actual diagnosis of RA. A 
register study can assess effectiveness such as the performance of a treatment plan 
in everyday practice. It was thus possible more reliably to catch those with RA who 
had purchased OP drugs in Finland, although the registers were not designed for 
such a study. The male-female ratio was 1:2.1, resembling the RA prevalence in 
Finland (Aho et al. 1989 and 1998). Those patients with RA who did not apply for 
special reimbursement for DMARD were naturally not caught.
GCs were gathered in 2000–05 because in 2006–07 some GC preparations 
did not qualify for reimbursement. Calcium and vitamin D preparations were 
also available over the counter, but many preparations were included in the 
reimbursement system and reimbursed (42%) to the patient if purchased in 
compliance with a doctor’s prescription. Data were gathered on these purchases. 
HRT was not included, being indicated mainly for reasons other than OP per se. 
The prescription register does not collect data on medications used in hospitals 
and institutions.
7.6 RESULTS IN RELATION TO OTHER STUDIES
Study I
There are earlier longitudinal studies of patients with RA exceeding a disease 
duration over 10 years and the follow-up time exteding to at least two years and 
using DXA for BMD measurements. Study populations have comprised only 
postmenopausal women in studies by groups under Hall (1994), Miyamoto (1999), 
Shibuya (2002). Comparing the study populations of Buckley (1997), Haugeberg 
(2002), Krieckaert (2013) to the population in study I there were also about the 
same proportion of men among postmenopausal women.
The cumulative dose of GC varied from 0.1 g to 78.3 g and the estimated mean 
daily dose of GC seldom exceeded 12 mg in these earlier studies. GC users in study I 
had a similar type of daily low dosage of prednisolon. Furthermore, the proportion 
of GC users in the population in study I resembles those in the studies by Hall 
(1994), Buckley (1997), Shibuya (2002), and Krieckaert (2013).
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GC users with RA in these earlier studies tended to have reduced BMD in the 
lumbar spine and the femoral neck compared to controls or the BMD reference 
population. Furthermore, the mean percentage change in BMD in the lumbar spine 
and femoral neck in patients with RA was negative in these studies (Hall et al. 
1994, Buckley et al. 1997, Miyamoto et al. 1999, Haugeberg et al. 2002, Shibuya et 
al. 2002). Krieckaert´s group (2013) found the percentage of BMD in the lumbar 
spine to become positive towards the end of their four-year follow-up. Likewise, 
the change in Z-score in the lumbar spine in patients in study I became positive 
during	the	five-year	follow-up.
Furthermore, Buckley and group (1997) found RA patients on both MTX and 
on prednisone at a daily dose of at least 5 mg to have lost their BMD in the lumbar 
spine	significantly	more	over	three	years	than	those	without	MTX.	Miyamoto	and	
colleagues	(1999)	found	that	BMD	in	the	femoral	neck	decreased	significantly	during	
the four years of follow-up in the GC group compared to a control group comprising 
RA patients only with NSAIDs. Six patients only used methotrexate periodically 
during the years 1991–96 in study I (Jäntti et al. 2002).
Haugeberg and colleagues (2002) found in RA patients who used antiresorptive 
drugs concurrently that their BMD loss was arrested at the hip. Use of vitamin 
D and calcium alone did not protect patients from the bone loss. Krieckaert and 
associates (2013) followed up 184 patients with RA and 41 (22%) of them used 
bishosphonates at entry to follow-up. They found that BMD in the hip decreased 
significantly	in	those	patients	who	were	not	on	bisphosphonates	during	their	four-
year follow-up. The limit of study I was that there were not data on OP drug use.
Stratifying annual BMD changes according to disease duration in patients with 
RA, Shibuya and colleaugues (2002) found that the annual reduction in BMD was 
least in patients with disease duration over 10 years. This is also in line with study I.
Study II
It would appear that premenopausal patients with RA had lost bone in the lumbar 
spine and femoral neck quite early in their disease course and those with GC even 
more so. Kalla and associates (2002) in a cross-sectional study of premenopausal 
women	with	RA	on	GC	at	a	mean	daily	dose	of	5mg/day	found	significantly	reduced	
BMD at the femoral neck compared to those without GC, but this was not the 
case in the lumbar spine. Tourinho and group (2005) in a cross-sectional study of 
patients	with	RA	of	relatively	short	duration	found	significantly	lower	BMD	in	the	
lumbar spine compared to controls. The daily dose of GC ranged from 1 to 30 mg.
BMD	 in	 study	 II	decreased	 significantly	 in	both	 lumbar	 spine	and	 femoral	
neck only in those RA patients with GC during the two-year follow-up, even when 
stratifying it in BMC values. Their median daily dose of prednisolone was only 5 mg.
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Use of HRT and OP drugs, especially together, seems to protect from bone loss 
(Hall et al. 1994). There were only regularly cycling premenopausal women in study 
II to avoid the confounding effect of postmenopausal bone loss. Use of HRT was 
not allowed in study II.
Study III
There are only a few earlier studies available on the subject of BMD in young adults 
with JIA (Havelka et al. 1993, Zak et al. 1999, Haugen et al. 2000, French et al. 2002, 
Aggarwal et al. 2006, Thornton et al. 2011). Subsets of JCA, JRA and JIA varied 
and oligo- and polyarticular subsets prevailed in these studies. The mean age of the 
subjects varied from 22.6 to 35.7 years and the mean disease duration was between 
12.4 to 27.1 years. The percentage of past or current GC users varied from 12.5 to 
57%.The oligoarthritis subtype of JIA prevailed in the JIA-inactive group, while 
the extended oligoarthritis and polyarthritis subtypes prevailed in the JIA-active 
group in study III. The percentage of GC users was higher in the JIA-active group.
BMD in the lumbar spine and in the hip in adult patients with JCA, JRA, and 
JIA appeared to be reduced compared to healthy controls in all these studies. 
Furthermore, osteopenia tended to prevail and its percentage varied from 23 to 
50% when measured at the lumbar spine or at the hip. Accordingly, the percentage 
of OP varied from 0 to 26.7%. In study III both JIA groups, active and inactive, 
had lower BMC values in the femoral neck than the controls, this especially among 
men.	There	was	no	significant	difference	in	weight-,	height-	and	sex-adjusted	BMC	
values in the lumbar spine between the JIA groups and the controls, nor was there 
any	significant	difference	between	men	and	women.	Accordingly,	the	percentage	
of OP was low 2.6 % in study III.
The remission criteria in patients with JIA still varied in earlier studies. Zak 
and associates (1999) found that the disease subtype of polyarticular course of 
JCA	seemed	to	be	associated	with	significantly	reduced	BMD	in	the	hip	while	20%	
patients with JCA were in remission. Haugen and colleaugues (2000) considered 
JA to be in remission when there was no disease activity and the patient had not 
taken medication for the past six months. Thus, 60% of the patients with JA were 
in	remission	in	their	study.	Both	men	and	women	with	active	JA	had	significantly	
lower BMD at all measured sites than healthy controls. JA patients in remission had 
a frequency of osteopenia similar to healthy controls and ten out of 229 patients 
had OP. 
The remission criteria in study III were the same as those implemented by 
Zak´s group (1999). Further, in the JIA active group the extended oligoarthritis and 
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polyarticular subtypes of JIA prevailed and the percentage of patients in remission 
(37%) was higher than that reported by Zak.
Predictive factors
Possible predictive factors for BMD, for example life-style factors in adolescence 
such as lack of participation in organized sports during adolescence, tobacco use 
during	adolescence,	and	lower	calcium	intake	during	adolescence	were	significantly	
associated with low BMD in earlier studies of JIA. Furthermore, revised Steinbrocker 
functional class >2 during adolescence, HAQ score, and joint deformities and 
limitation of joint movements correlated negatively with BMD (Zak et al.1999, 
French et al. 2002). Weight, height, GC use, ESR, disease activity and bone turnover 
were associated with BMD both in the lumbar spine and in the femoral neck, but 
age was associated with BMD in the femoral neck. BMI correlated positively with 
BMD (Haugen et al. 2000, Aggarwal et al. 2006, Thornton et al. 2011).
GC use, weight and height, but not disease activity, showed same association 
with lower BMC in study III. Predictive factors for bone mass development depend 
on study population and study design (Kröger et al. 1992a, 1992b, Jones et al. 1994, 
Greenspan et al. 1994, Blum et al. 2001, Pesonen et al. 2005). The limitation of 
studies I, II, and III is that no reliable data were available on life style factors and 
exercise.
Study IV
Studies of implementation of OP prevention in patients with RA rely on patient 
chart reviews, on questionnaires or multicenter studies (Soucy et al. 2000, Thiele 
et al. 2005, Solomon et al. 2006, Wall and Walker-Bone 2008, Ledwich and Clarke 
2009, Barrett-Connor et al. 2009, Heberlein et al. 2011, Gamez-Nava et al. 2013). 
Numbers of participants in these studies are low compared to those in study IV, 
which	benefited	from	access	to	nation-wide	register	data	over	a	number	of	years.	
It was possible to verify actual purchases of OP drugs in study IV.
Predictors for OP management in these earlier studies were older age, female 
gender, GC dosage, prior fracture, and diagnosis of OP. This is in line with study 
IV, but the percentage of OP treatment users was lower than in previous works. 
Furthermore, in study IV it was estimated that the use of OP drugs increased over 
time and the use was more frequent among patients with known risk factors for 
OP and fracture.
65
8 CONCLUSIONS
1. In a long-term disease course at the 15-year check-up about third of the patients 
with rheumatoid arthritis had osteoporosis and about half osteopenia according 
to the T-score. At the 20-year check-up the mean Z-score had increased 0.45 at 
the lumbar spine and decreased only 0.20 at the femoral neck. Correspondingly, 
the mean change in BMD was 0.01 g/cm² in the lumabr spine and 0.02 g/
cm²	in	the	femoral	neck	during	the	five	years	of	follow-up.	None	of	the	studied	
parameters explained patients’ bone loss.
2.  Premenopausal rheumatoid arthritis women with and without glucocorticosteroid 
treatment and the controls lost bone according to bone mineral content 
statistically similarly during the two years of follow-up. Comparing results on 
bone mineral density change between the three groups it is relevant to report 
changes both in bone mineral content and in projectional area to clarify the 
basics of the bone mineral density change. The amount of bone loss due to 
treatment with low-grade prednisolone remains controversial. 
3.  The male and female young adults with juvenile idiopathic arthritis had lower 
weight- and height-adjusted bone mineral density values in the femoral neck 
than the healthy controls, but only 2.6% had osteoporosis. Comparing bone 
mineral content values in the femoral neck in both men and women with active 
or inactive juvenile idiopathic arthritis a difference was found among men. 
Glucocorticosteroid use and weight were associated with bone mineral content 
in the femoral neck in both men and women with juvenile idiopathic arthritis. 
Among women GC use and height were also associated with BMC both in the 
lumbar spine and femoral neck.
4. A total of nine per cent of patients with rheumatoid arthritis had purchased 
osteoporosis	 drugs,	 mainly	 bisphosphonates,	 during	 the	 first	 year	 after	
commencement of antirheumatic treatment. Of glucocorticosteroid users, 14% 
of women and 6% of men were prescribed osteoporosis drugs, whereas in those 
who did not have glucocorticosteroids the percentage was 8% for women and 
3% for men. Patients with early rheumatoid arthritis were increasingly receiving 
osteoporosis drugs, and use was more frequent among patients with known 
risk factors and among women. OP drug use according both ACR and EULAR 
recommendations for the prevention of OP in patients with rheumatic diseases 
and those who receive GC treatment was of low degree, but improving.
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CONCLUSIONS
Study results suggest that bone loss takes place in earlier disease course in RA and 
JIA and bone loss is in the long-term disease course in RA of low degree. Further 
studies are needed to elucidate bone loss and osteoporosis development in early 
rheumatoid arthritis and to better focus the timing and means of osteoporosis 
prevention.
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